Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

Yu-Wen Zhou1,2, Yao Xie2,3, Lian-Sha Tang1,2, Dan Pu4, Ya-Juan Zhu1,2, Ji-Yan Liu1,2* and Xue-Lei Ma1,2*

Owing to the limitations of the present efforts on drug discovery against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of the understanding of the biological regulation mechanisms underlying COVID-19, alternative or novel therapeutic targets for COVID-19 treatment are still urgently required. SARS-CoV-2 infection and immunity dysfunction are the two main courses driving the pathogenesis of COVID-19. Both the virus and host factors are potential targets for antiviral therapy. Hence, in this study, the current therapeutic strategies of COVID-19 have been classified into “target virus” and “target host” categories. Repurposing drugs, emerging approaches, and promising potential targets are the implementations of the above two strategies. First, a comprehensive review of the highly acclaimed old drugs was performed according to evidence-based medicine to provide recommendations for clinicians. Additionally, their unavailability in the fight against COVID-19 was analyzed. Next, a profound analysis of the emerging approaches was conducted, particularly all licensed vaccines and monoclonal antibodies (mAbs) enrolled in clinical trials against primary SARS-CoV-2 and mutant strains. Furthermore, the pros and cons of the present licensed vaccines were compared from different perspectives. Finally, the most promising potential targets were reviewed, and the update of the progress of treatments has been summarized based on these reviews.

INTRODUCTION

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in December 2019 and has rapidly become a pandemic.1 SARS-CoV-2 has a long incubation period of up to 33 days (in some studies, incubation period of >14 days was registered in >5% of patients with traced contacts)2 and a rapid transmission speed, faster than those of other coronaviruses, including SARS-CoV and the Middle East respiratory syndrome (MERS)-CoV. Moreover, asymptomatic carriers may also spread the virus.3–5 Most patients infected with SARS-CoV-2 exhibit mild-to-moderate symptoms; however, approximately 15% progress to severe pneumonia4 and approximately 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure, and even death.6,7 Owing to the abovementioned characteristics, as of June 1, 2021, COVID-19 spread to >200 countries leading to >170,000,000 identified cases with 3,782,490 confirmed deaths.8 The pandemic has increased the susceptibility of humans to microbial pathogens and has revealed the gaps in our therapeutic arsenal; scientists are working at unprecedented speed to understand the disease and to find a cure.

Currently, two main courses are believed to drive the pathogenesis of COVID-19. In the early stage of infection progression, it is primarily driven by the identification, fusion, entry, and replication of SARS-CoV-2, also called as the replication cycle, which is mainly modulated by viral proteins. In the late stage of infection progression, it is driven by a tremendous inflammatory/immune response to SARS-CoV-2 that results in tissue damage. Thus, both the proteins of the virus and host factors are essential for the pathogenesis of COVID-19 and are promising potential targets for antiviral therapy (Fig. 1).

In this review, based on the above described understanding of the pathogenesis of COVID-19, the therapeutic targets and interventions of COVID-19 have been classified into “target virus” and “target host” categories. A comprehensive analysis of the therapeutic targets has been conducted based on the viral and host factors, occurring at the levels of DNA, RNA, and proteins, involving both classic and novel important signaling pathways and even comprising the promising epigenetic mechanisms, which would contribute to SARS-CoV-2 infection (Fig. 2). Furthermore, a profound analysis has been performed on the highly acclaimed current therapeutic strategies of COVID-19, both based on “target virus” and “target host” categories. Because drugs are being repurposed, emerging approaches and promising potential targets are the implementations of the above two strategies. First, a comprehensive review of the highly acclaimed old drugs was performed according to evidence-based medicine, and the mechanism, potential targets, and already shown clinical data of these drugs were summarized to prepare guidelines for repurposing drugs. Additionally, their unavailability in fighting COVID-19 has been analyzed and summarized. Next, a profound analysis of the emerging drugs has been conducted, particularly including all licensed vaccines and monoclonal antibodies (mAbs). Furthermore, pros and cons of the present licensed vaccines have been compared from different perspectives.

*Correspondence: Ji-Yan Liu (liujiyan1972@163.com) or Xue-Lei Ma (drmaxuelei@gmail.com)

This article was published as part of the special issue “COVID-19: mechanisms and clinical studies” in Signal Transduction and Targeted Therapy (2021) 6:317

Received: 9 April 2021 Revised: 27 June 2021 Accepted: 14 July 2021
Published online: 26 August 2021

© The Author(s) 2021
Regarding mAbs, the efficacy, adverse events, and administrations of these non-negligible treatments in the management of SARS-CoV-2 have been analyzed. Current vaccines and mAbs have demonstrated efficacy against COVID-19. However, increasing number of mutations emerged worldwide, and these variants pose a significant challenge to current treatments. Thus, the most popular mutations have been summarized, and the efficacy of current licensed vaccines and mAbs against these variants has been reviewed. Finally, the most promising potential targets were reviewed, and preclinical novel drugs were enumerated based on them.

**PATHOGENIC MECHANISM**

As mentioned above, two main courses between virus and host are thought to drive the pathogenesis of COVID-19: the so-called replication cycle of SARS-CoV-2 and the tremendous inflammatory/immune response to the virus. The fierce virus–host interactions could cause damage to tissues and organs, resulting in severe COVID-19.

During the early stage of infection, the structural integrity and normal functions of virus-related proteins are vital for the virus replication cycle. The structural proteins of SARS-CoV-2 mainly comprise spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. Among these, S, M, and E proteins are embedded in the envelope of viral surface, whereas N protein is located in the core of ribonucleoprotein to form the capsid outside.\(^9\,^{10}\) S protein exists as a homotrimer in the virion envelope and contains membrane-distal S1 and membrane-proximal S2 subunits.\(^11\,^{12}\) S protein is associated with the process of virus entry by receptor recognition and fusion mediation. M and E proteins help in the assembly and production of the virion. N protein binds with viral genome and contributes to the virus release. SARS-CoV-2 initiates its invasion after the virus entry into the nasopharynx mucosa. Once the receptor-binding domain (RBD) of S1 subunit directly binds with the angiotensin-converting enzyme-2 (ACE2) of the epithelial cells in the nasopharynx, S1 subunit dissociates, and meanwhile, the spring-loaded S2 subunit refolds, which is conducive for membrane fusion.\(^13\,^{14}\) Notably, the activation of the S protein RBD requires the cleavage of polybasic S1/S2 or S2’ site on the host cell surface by the host proteases, including endosomal cathepsin L (CatL) or transmembrane protease serine 2 (TMPRSS2),\(^15\,^{16}\) followed by which the S protein experiences conformation change to facilitate membrane fusion between the virus and host cell. Therefore, receptor binding and proteolytic activation are two primary processes of virus entry. The higher combination affinity of ACE2 with RBD in SARS-CoV-2 promotes virus entry (Fig. 3).

The biological events that subsequently occur include replication, assembly, and release of virus. The protease of the virus (PLpro) is required to form a proper functional replicase complex and promote viral spread. After the viral genome enters the host cell cytoplasm, it gets translated into replicate proteins (open reading frame 1a/1b (ORF1a/1b)), subsequently undergoing cleavage to form individual nonstructural proteins (Nsp5) by PLpro, resulting in the formation of RNA-dependent RNA polymerase (RdRp).\(^17\) The endoplasmic reticulum (ER) is rearranged by the replicase to form double-membrane vesicles, which are involved in the regulation of replication and transcription of virus (subgenomic RNA (sgRNA)). The transcription of sgRNA results in the formation of structural and accessory proteins. The sgRNAs are inserted into the ER and then moved to the ER–Golgi intermediate compartment for viral budding. Ultimately, the genome enveloped in the N protein assembles to incorporate new virions, which are transported in the vesicle and secreted...
from the membrane through exocytosis.18 Newly encapsulated virus invades other cells and infiltrates body organs owing to blood flowing from the nasal, oral, pulmonary, and the predominant infective body site,19 leading to multiple organ impairments in the disease development.20 Furthermore, the invasive virus and attacked cells strongly trigger uncontrolled "cytokine storm" with hyperinflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and IL-1β.21,22 Several studies have also demonstrated the important roles of SARS-CoV-2 viral proteins in the innate and adaptive immunity. Innate immunity is primarily known as the first line to resist foreign agents. This system is rapid, evolutionary, and nonspecific.23 Phagocytic leukocytes, epithelial cells, and soluble immune mediators fundamentally comprise the lung innate immune system. When S protein binds with ACE2, the innate immune reaction may get activated via the stimulating nuclear factor κB (NF-κB) cascade in epithelial cells, monocytes, and macrophages.24 Then SARS-CoV-2 escapes the host antiviral defenses by employing immune blunting or delay, allowing either rapid replication or by promoting inflammatory reaction.25,26 In reverse, several innate immune-associated proteins are targeted by coronavirus proteins. PLpro participates in cleaving host proteins as an evasion mechanism against antiviral immune responses.27–29 SARS-CoV-2 distinctively interacts with the amino-terminal ubiquitin-like domain of the ubiquitin-like interferon (IFN)-stimulated gene 15 (ISG15), an important innate immune regulator of host cell. Moreover, preferential cleavage of ISG15 by PLpro may attenuate type I IFN-signaling pathway, an essential component in antiviral response, and IFN responsive factor 3 (IRF3)30 (Fig. 4). Other proteins of SARS-CoV-2, including structural protein called N protein and accessory proteins called ORF6 and ORF8, were also demonstrated to be potential inhibitors of type I IFN pathway. Moreover, a clinical study demonstrated the absence of detectable type I IFN in patients with COVID-19.31 Apart from NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), inflammasome also attracted much attention in the innate immunity response caused by SARS-CoV-2. The binding of S protein and the ACE2 receptor can activate the NLRP3 inflammasome, resulting in pyroptosis.32 Subsequently, host cells may die from pyroptosis, after which the pyroptotic epithelial cells can release a large number of virions, which is important for efficient dissemination of SARS-CoV-2 and is also referred to as damage-associated molecular patterns (DAMPs).33 The DAMPs trigger multiple signaling pathways, including retinoic acid-inducible gene I and mitochondrial antiviral signaling (MAVS)34 and autophagy,31 thereby finally inducing the transactivating activities of NF-κB and IRF3 and further producing type I IFN and proinflammatory inhibitors.23 Additionally, because the E protein of SARS-CoV allows calcium (Ca2+) transport, changes in the Ca2+ level in the cytosol would trigger NLRP3 inflammasome pathways.36 Owing to the structural similarity between SARS-CoV-2 and SARS-CoV, a hypothesis that the E protein of SARS-CoV-2 regulates the NLRP3 signaling pathway has been proposed.36 Furthermore, several coronavirus accessory proteins affecting the function of NLRP3 inflammasome, including ORF3a, have been identified to be involved in the NLRP3 inflammation activation.36 These findings need to be experimentally validated further both at basic and clinical levels.

Consistently, the important roles of SARS-CoV-2 viral proteins in the adaptive immunity were also demonstrated. Adaptive immune system can develop protective immunity by responding to pathogens in an antigen-specific manner. There are mainly two kinds of immune cells that comprise the adaptive immune system: B cells and T cells. In vitro, peripheral blood mononuclear cells can be stimulated with peptide pools derived from individual N, M, or S proteins. It has been well established that CD4+ and CD8+ T cells specific for the peptide pools derived from N, M, and S SARS-CoV-2 proteins are detected in the blood of patients with COVID-19.37 M protein-reactive CD4+ T cells are the most polyfunctional with increased frequencies of IFN-γ, IL-2, and TNF-α, followed by S
Finally N protein-reactive CD4\(^+\) T cells. Although CD8\(^+\) T cells were characterized by the production of IFN-\(\gamma\), the concentration of CD8\(^+\) T cells was lower than that of CD4\(^+\) T cells. Another clinical study found that the level of IFN-\(\gamma\) in response to N or S proteins was higher in patients with mild infection than in severe cases. Clinical factors, including age and sex, were also associated with CD8\(^+\) T cell response and COVID-19 prognosis. In patients with severe COVID-19, lung-infiltrating CD8\(^+\) T cells showed T cell exhausted status with upregulated PD-1 and Tim-3 markers. Moreover, in patients with mild COVID-19 having CD8\(^+\) T cells “non-exhausted” profile, SARS-CoV-2-reactive cells increased in frequency and presented with lower inflammatory characteristics and cytotoxicity. In contrast, in patients with severe disease with CD8\(^+\) T cell “non-exhausted” profile, SARS-CoV-2-reactive cells showed the stimulation of prosurvival NF-\(\kappa\)B and anti-apoptotic pathways. Cumulatively, patients with severe COVID-19 showed robust CD8\(^+\) T cell memory responses. These results may highlight that CD4\(^+\) T cells play a role in the pathogenesis of COVID-19, whereas CD8\(^+\) T cells are beneficial. Regarding antibody responses, the RBD domain of the SARS-CoV-2 S protein is the primary target of these viral-neutralizing antibodies (nAbs). Immunoglobulin G (IgG) and IgA were detected in almost all COVID-19 cases, and the positive detected rate of IgM was lower than that of IgG and IgA. The level of IgG, IgM, and IgA titers was consistent with RBD Ig. Moreover, multiple studies further measured functional antibodies, and the nAbs were almost detected in all subjects. Of note, the titer of nAb was associated with RBD IgG and IgA; these findings further confirmed that RBD is the primary target of nAbs in SARS-CoV-2 infection. The fierce virus–host interactions could cause damage to tissues and organs, resulting in severe COVID-19. Moreover, increasing number of mutations emerged worldwide.

TARGET VIRUS

Antitentry Repurposing drugs. Entry is the first step for SARS-CoV-2 to invade host cells. Structural proteins play an important role in this process. As mentioned above, the structural proteins of SARS-CoV-2 mainly comprise S, M, E, and N proteins. Therapeutic strategies are designed to target key elements of structural proteins to inhibit viral entry. Several drugs were considered to have antitentry effect and were repurposed in COVID-19.

Fig. 3 Structure of SARS-CoV-2, spike (S) protein-mediated membrane fusion, and potential therapy against the spike protein. SARS-CoV-2 comprises four structural proteins: S, M, E, and N proteins. Specifically, S protein is composed of two functional subunits, S1 subunit for attachment and S2 subunit for fusion. S1 subunit is composed of NTD and CTD. S1 subunit exerts its effects primarily through RBD in CTD. S2 subunit is made up of FP, a helix–turn–helix structure formed by HR1 and HR2 around a CH, CD, TM, and CT. SARS-CoV-2 is recognized by the binding of RBD and ACE2. Next, the S protein could be hydrolyzed by host proteases at the cleavage spots of S1/S2 (furin) and S2 (TMPRSS2). Then the conformation of S protein is irreversibly changed to further activate the release of the FP structural constraints. S2 subunit is folded to form antiparallel 6-HB by three HR2 segments folding into the grooves on the surface of the HR1 inner core, thereby resulting in the lipid membrane fusion of the virus and the host. Three drugs could fight with S protein containing vaccines and nAbs against S protein and recombinant HR1/HR2 peptides against 6-HB formation. Vaccines against S protein play their role via antigen presentation, cytokine stimulation, and antibody production, whereas nAbs directly bind to S protein to fight with it.
Umifenovir, also called Arbidol, is a small indole-derivative molecule approved for the prevention and treatment of influenza and other viral infections in the respiratory system in Russia and China. Umifenovir could stabilize the membrane and/or mask the viral residues in receptor recognition sites, thereby impeding the attachment of the virus to the plasma membrane. This might impact viral entry.\(^4\)\(^7\) Some studies have demonstrated favorable clinical response with umifenovir plus lopinavir/ritonavir.\(^4\)\(^9\) Nojomi et al. have reported that umifenovir showed significant clinical and laboratory improvements, including peripheral oxygen saturation, intensive care unit (ICU) admissions, duration of hospitalization, chest cytoplasmic tail (CT) involvements, white blood cell, and erythrocyte sedimentation rate level, compared with lopinavir/ritonavir.\(^6\) However, a meta-analysis that included 12 clinical trials and 1052 patients showed no evidence to improve COVID-19 outcomes.\(^5\) Nelfinavir (Viracept), a kind of protease inhibitor, has been used as an antiretroviral drug in human immunodeficiency virus (HIV) treatment.\(^5\) Recent experiments have suggested that nelfinavir inhibits S-n- and S-o-mediated cell fusion resulted from SARS-CoV-2 S glycoprotein, thus inhibiting membrane fusion.\(^5\)\(^3\)\(^4\) However, no clinical data are available for nelfinavir.

Chloroquine (CQ) is an antimalarial drug, and hydroxychloroquine (HCQ) is a CQ analog used in treating autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. HCQ could increase the endosomal pH, thus inhibiting the fusion of SARS-CoV-2 and the host cell membranes.\(^5\)\(^5\)\(^4\) Additionally, CQ may interfere with the binding of SARS-CoV-2 to the cell membrane by inhibiting the glycosylation of cellular ACE2 receptor.\(^5\) An in vitro experiment also suggested an immunomodulatory effect of CQ and HCQ.\(^5\) Therefore, the efficacy and safety of CQ and HCQ for COVID-19 treatment have been assessed in multiple clinical trials. Unfortunately, compared with the usual standard of care, HCQ did not decrease the 28-day mortality but increased the length of hospital stay and risk of intervention of invasive mechanical ventilation or death.\(^5\)\(^9\) Therefore, based on the existing evidence, HCQ did not improve the clinical outcomes in hospitalized patients with mild-to-moderate COVID-19, but more adverse events occurred compared with standard care.\(^5\)\(^0\) Moreover, HCQ with azithromycin showed no benefit for HCQ among hospitalized patients with COVID-19 in retrospective observational studies.\(^6\)\(^1\)\(^2\) In June 2020, Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) of CQ and HCQ in treating certain hospitalized patients with COVID-19\(^6\)\(^3\) because FDA suggested that CQ and HCQ are unlikely to be effective in COVID-19 and result in serious adverse events, including cardiac adverse event based on former evidences. Thus, CQ or HCQ with or without azithromycin for treating hospitalized (AI) and nonhospitalized (AII) patients with COVID-19 has not been recommended by the COVID-19 Treatment Guideline Panel (CTGP).

Remarkably, repurposing drugs that might inhibit the entrance of virus into host cell have not shown clinical preference. The main mechanisms of these repurposed drugs remain uncertain, and the interaction sites of new approaches are relatively clear. Next, the structure-based pathogenic mechanisms and new therapeutic strategies of COVID-19 are summarized.

**Spike glycoprotein.** S protein, a highly N-glycosylated protein of approximately 180 kDa, has been the most widely studied target in SARS-CoV-2.\(^6\) The cryo-electron microscopic structure of S protein exists as a homotrimer in the virion envelope, which contains two functional subunits: membrane-distal S1 and membrane-proximal S2 subunits.\(^1\)\(^1\)\(^2\)\(^7\)\(^2\) The former is composed of N-terminal domain (NTD) and RBD, whereas the latter comprises fusion peptide, connector domain (CD), a helix–turn–helix structure formed by heptad repeat 1 (HR1) and heptad repeat 2 (HR2) around a central helix, transmembrane domain (TM), and CT.\(^6\) The noncovalent bind form of S1 and S2 usually presents in several CoVs before fusion.\(^6\)\(^6\)\(^7\)\(^0\) S1 subunit exerts its effects on recognizing and binding protein-based receptors primarily via RBD.\(^7\)\(^1\) Thus, the RBD of S protein exerts its effects on binding ACE2 specifically, which is a significant target for antiviral drugs and vaccines.\(^7\)\(^2\)\(^7\)\(^4\) Additionally, NTD is reported to be involved in sugar-based receptor binding, virus attachment, and the S protein transition in pre- or post-fusion.\(^7\)\(^2\)\(^7\)\(^4\) S2 subunits are responsible for mediating cellular and virus–membrane fusion. Notably, S1 subunit also contributes in stabilizing the prefusion status of biomembrane-anchored S2 subunit.\(^7\)\(^6\)

Owing to the presence of N-linked glycan, the S trimer could guarantee proper folding and modulate the interaction of mAbs with host proteases. Therefore, the S protein, particularly the RBD of S protein, has been the potential target for COVID-19 drug development. The majority of these novel drugs have been researched into the clinical trial phase. From the perspective of dispensing SARS-CoV-2, this study focuses on the current licensed vaccines and mAbs for the EUA\(^6\)\(^4\)\(^7\)\(^4\)\(^8\) which have been applied in the clinic, with the hope that these could indicate direction and shed light on ways to tackle SARS-CoV-2.
Vaccines of SARS-CoV-2. Since the fast, unprecedented entry of the first SARS-CoV-2 vaccine candidate on March 16, 2020,81–83 216 vaccines underwent preclinical development and 100 are undergoing clinical trial (Supplementary Table 1) worldwide (https://biorender.com/covid-vaccine-tracker) as of May 27, 2021. Presently, more than five kinds of vaccines announced by the Chinese Health Commission are developed for SARS-CoV-2 in China, including influenza viral vector vaccine, adeno-viral vector vaccine, inactivated vaccine, nucleic acid vaccine, and subunit protein vaccine. The advantages, disadvantages, and optimal strategies of each type of vaccines have been summarized in Fig. 5. Moreover, 11 vaccines have been licensed or approved for EUA (Table 1). The details of each licensed and EUA vaccines were thoroughly analyzed and compared to provide instructions for the clinical application of these vaccines.

To date, 11 vaccines for SARS-CoV-2 have been licensed or approved by EUA worldwide; these vaccines are of the following four types: viral vector-based vaccine, RNA-based vaccine, inactivated virus vaccine, and protein subunit vaccine. Virus-like particle vaccines may still need time to evaluate their efficacy and safety owing to the temporarily insufficient progress of clinical trials. The licensed vaccines are Sputnik V in Russia and Ad5-nCoV and three inactivated vaccines in China. The EUA vaccines include BNT162b2, mRNA-1273, and Ad26.COV2.S in America; Covishield in England; Covaxin in India; and ZF2001 in China.

Efficacy and safety: The efficacy and safety of developing vaccines against COVID-19 should be given an overarching priority. Among these 11 vaccines, BNT162b2 was developed by Pfizer/BioNTech84 and mRNA-127385 was developed by Moderna, with the highest efficacy at 95% and the second highest efficacy at 94.1%, respectively; these are RNA-based vaccines. The most common adverse event of these two RNA-based vaccines was injection-site pain, which was slightly higher in BNT162b2 (66–78%) than in mRNA-1273 (60%). As the first licensed vaccine, on the basis of Ad26 and Ad5, Sputnik V86 displayed the third highest efficacy at 91.6% with the largest adverse response proportion of flu-like illness presented at 15.2%. Although the production of Sputnik V was criticized for absence of transparency, corner cutting, and unevenly haste87–89 at first, the positive results of phase III clinical trials demonstrated the scientific and clear principle vaccination, which suggests the potential of reducing the incidence of SARS-CoV-2.

In terms of inactivated virus vaccines, three of the four licensed vaccines are from China. The main differences among these three vaccines are the different virus strains derived from different patients. CoronaVac developed by Sinovac uses CN02 strain, whereas SARS-CoV-2 vaccines (Vero Cell) developed by the Beijing Institute of Biological Product (BIBP) and Wuhan Institute of Biological Product (WIBP) used HBo2 strain and WIV04 strain, respectively.90–92 The highest overall protective efficacy shown by SARS-CoV-2 vaccines (Vero Cell) was developed by BIBP (BIBBP-CovV) at 79.34%. Sinovac conducted the phase III clinical protocol in Brazil, Chile, Indonesia, and Turkey. The results in Turkey showed more favorable efficacy at 91.25% than those in Chile at 67% and Brazil at 50.65%.93 Although the same batch and immunization schedule of vaccines were applied in these four countries, the significant difference, which was evident in the efficacy, may be owing to the distinct race characteristics. SARS-CoV-2 vaccine (Vero Cell) produced by WIBP was licensed recently on February 25, 2021 for which the efficacy obtained was 72.51%. Among these three vaccines developed in China, WIBP-CovV displayed the smallest proportion of the most common and the second common adverse reactions, comprising injection-site pain and fever at 14.3 and 2.4%, respectively. Apart from these, diarrhea, fatigue, swelling, and headache have been reported with low incidence among the adverse events of these three vaccines.
Table 1. The characteristics of the licensed and EUA vaccines

| Vaccine platform description | License code | Composition | Developers | Country | Licensed date | Approval type | Route of administration | Number of doses | Schedule | Regimen | Efficacy to SARS-CoV-2 | Adverse events | Storage condition | Price Protection | Expected supply |
|-----------------------------|--------------|-------------|------------|---------|--------------|---------------|------------------------|----------------|----------|---------|-----------------------|----------------|------------------|-----------------|---------------|
| Vial: vector-based vaccines | Sputnik V    | rAd26-S + rAd5-S | Gamaleya Russian Federation | Russia | Aug 11, 2020 | Licensed IM | Day 0 and Day 21 | First dose rAd26, second dose rAd5 | 2 | 91.6% | Flu-like illness (1.5%), injection-site reactions (5.4%), headache, asthenia | Severe adverse events (0%): infection, hemolytic anemia, transverse myelitis | Liquid (stored at −18°C) and freeze-dried (stored at 2–8°C) | $10 At least 6 months | 500 million |
| Covishield                  | ChAdOx1-S    | AstraZeneca + University of Oxford | England | Jan 2021 | EUA IM | Day 0 and Day 28 | (1): COV001 (UR): a dose of SD (5 × 10^10 VLPs) + a booster dose; (2): COV002 (UK): LD (2.2 × 10^10 VLPs) + a SD; (3): COV003 (Brazil): two doses (3.5 × 6.5 × 10^10 VLPs); (4): COV004 (South Africa): two doses (5.5 × 6.5 × 10^10 VLPs) | 2 | 66.7% | All: 66.7%; LD: 80.7%; SD: 63.1% | Injection-site pain (5.6%), fatigue (4.2%), fever (32%), headache (29%) | Stored and distributed at 2–8°C for 2 years, stored and distributed at 2–8°C for 6 months, distributed at 2–8°C up to 3 months | $4–$8.1 At least 6 months | 30 million |
| Ad26COV2.S                  | Ad2S-5       | CanSino + BIB | China | Feb 25, 2021 | Licensed IM | Day 0 | 5 × 10^10 VLPs | 14 days after injection: 68.83%; 28 days after injection: 65.28% | 1 | 66% | Injection-site pain (4.86%), headache (3.89%), fatigue, myalgia, nausea | Injection-site pain (9%): injection-site pain, headache, fever, myalgia, nausea | Stored and distributed at 2–8°C | $10 At least 6 months | 1 billion |
| RNA-based vaccine           | BNT162b2     | LNP-Formulated, nucleoside-modified RNA | Pfizer/BioNTech | Dec 11, 2020 | EUA IM | Day 0 and Day 28 | 30 μg | Injection-site pain (6.6–7.8%), fatigue (4%), headache, lymphadenopathy, Bell’s palsy | Injection-site pain (17%), fever (2.4%), diaphoresis, fatigue, myalgia, Bell’s palsy | Stored and distributed at 2–8°C for 2 years, stored and distributed at 2–8°C for 6 months, stored and distributed at 2–8°C for 6 months, distributed at 2–8°C up to 5 days | $19.5 At least 6 months | 50 million |
| mRNA-1273                   | BNT162b2     | LNP-Formulated, nucleoside-modified RNA | Moderna | Dec 18, 2020 | EUA IM | Day 0 and Day 28 | 100 μg | Injection-site pain (60%), fatigue (20%), myalgia, Bell’s palsy | Injection-site pain (4.1%): injection-site pain, headache, fever, myalgia, Bell’s palsy | Stored and distributed at 2–8°C for 6 months, ready to use (2–8°C) up to 5 days | $25–$37 At least 6 months | 50 million |
| Inactivated virus           | BBP-CovVac   | Inactivated virus (HB02 strain) (Vero cell) + alum as adjuvant | Sinopharm + CNB = BIB | China | Dec 31, 2020 | Licensed IM | Day 0 and Day 21 | 4 μg/0.5 mL | Injection-site pain (3.5%): injection-site pain, headache, swelling, fatigue | Injection-site pain (0.3%): injection-site pain, headache, swelling, fatigue | Stored and distributed at 2–8°C | Free At least 6 months | 1 billion |
| Covaxin                    | Whole-virion inactivated | Bhaat Biotech | India | Jan 3, 2021 | EUA IM | Day 0 and Day 14 | 6 μg/0.5 mL | Injection-site pain (3.2%), headache (2%), fever (1.3%), myalgia | Injection-site pain (1.7%): injection-site pain, headache, fever (2.4%), diaphoresis, fatigue, swelling | Stored and distributed at 2–8°C | NA At least 6 months | 300 million |
| CoronaVac                  | Inactivated virus (CN02 strain) (Vero cell) + alum as adjuvant | SinoVac | China | Feb 5, 2021 | Licensed IM | Day 0 and Day 14 | 3 μg/0.5 mL | Injection-site pain (1.7%): injection-site pain, headache, fever, myalgia | Injection-site pain (1.3%): injection-site pain, headache, fever (2.4%), diaphoresis, fatigue, swelling | Stored and distributed at 2–8°C | Free At least 6 months | 2 billion |
| Protein subunit            | WIBP-CovVac  | Inactivated virus (WIV04 strain) (Vero cell) + alum as adjuvant | Sinopharm + CNB = WIBP | China | Feb 25, 2021 | Licensed IM | Day 0 and Day 21 | 5 μg/0.5 mL | Injection-site pain (1.4%): injection-site pain, headache, fever (2.4%), diaphoresis, fatigue, swelling | Injection-site pain (1.9%): injection-site pain, headache, fever (2.4%), diaphoresis, fatigue, swelling | Stored and distributed at 2–8°C | NA At least 6 months | 1 billion |
| ZF2001                     | An RBD-dimer protein produced in Chinese hamster ovary (CHO) cells with alum as adjuvant | Anhui Zhifei Longyao Biopharmaceutical Institute of Microbiology, Chinese Academy of Sciences | China | Mar 10, 2021 | EUA IM | Day 0 + 28 + 56 | 25 μg/0.5 mL | Seroconversion rates: 97% | Seroconversion rates: 97% | Seroconversion rates: 97% | Seroconversion rates: 97% | Stored and distributed at 2–8°C | NA At least 6 months | 30 million |

*MAdS recombinant adenovirus 5, rAd26 recombinant adenovirus 26, S Spike (protein), ChAdOx1-S attenuated resulting in infections in chimpanzees, LNP lipid-based nanoparticles, BIB Beijing Institute of Biotechnology, BIBP Beijing Institute of Biological Product, WIBP Wuhan Institute of Biological Product, CNB China National Biotec Group, EUA emergency use authorization; LD low dose; SD standard dose, BD booster dose, VLP virus-like particles.*
2–8 °C for a month and even at room temperature for up to 5 h. The other vaccines could universally be stored at 2–8 °C for 6 months, thereby greatly enhancing their universality.

The price of the vaccines disclosed on the Internet may not be the final price when released. Considering the present data, Covishield presented the lowest price at $4–58.1, and it has been granted conditional marketing authorization or emergency use in >50 countries. At present, World Health Organization (WHO) will accelerate the access to the vaccine in up to 142 countries through COVID-19 Vaccine Global Access (Covax) (https://www.astrazeneca.com/covid-19.html).

According to the WHO target product profiles for SARS-CoV-2 vaccines,100 the protection duration is required for at least 6 months. Currently, no exact duration data of the licensed or EUA vaccines has been published online, and further evaluation remains to be performed.

All the vaccine companies begin to ramp up the production after the approval. CanSino proposed to supply 5 million vaccines during 2021, the highest production of the estimated supply. Janssen, Sinopharm/BIBP, Sinopharm/WIBP, and Sinovac stated that 1 million supply could be utilized in this year.

**mAbs of SARS-CoV-2**

Bamlanivimab, also known as LY3819253 and LY-CoV555, is a neutralizing mAb that binds to the RBD of the S protein of SARS-CoV-2.101–103 A randomized controlled phase I/I trial (BLAZE-1 study) compared bamlanivimab (three doses: 700, 2800, and 7000 mg) with placebo.103 The primary outcome was SARS-CoV-2 virus load reduction from day 1 to day 11. The results showed that antibody induced by 2800-mg dose experienced significant decrease than that induced by placebo. Meanwhile, the 700- and 7000-mg groups had no tendency of notable reduction, possibly because these patients had been effectively cleared from SARS-CoV-2 before day 11. The most common adverse event of bamlanivimab was nausea (3.9%), followed by dizziness (3.2%) and moderate infusion responses (2.3%). Bamlanivimab group showed decreased severity of symptoms and hospitalization proportion compared with the placebo group. On November 10, 2020, bamlanivimab was issued EUA for patients with mild-to-moderate COVID-19 (pediatric and adults).104 The authorized administration is the single 700-mg dose with vein injection infusion for >60 min. If a patient tests positive for SARS-CoV-2 or the onset of symptoms of infection was <10 days, this drug should be utilized as soon as possible105 (Bila).

Bamlanivimab plus etesevimab: Bamlanivimab and etesevimab (LY-CoV016) are neutralizing mAbs that target different but overlapping epitopes in the RBD of the S protein of SARS-CoV-2. Bamlanivimab plus etesevimab: Bamlanivimab and etesevimab group also showed superior death and hospitalization rate than the placebo group. On March 5, 2021, the European Medicines Agency has allowed EU Member States to utilize bamlanivimab plus etesevimab for emergency use in patients with COVID-19.109

Casirivimab plus imdevimab: Casirivimab (REGN10933) and imdevimab (REGN10987) constitute a combined cocktail (REGN-COV2) that targets the RBD of the S protein of SARS-CoV-2.80 A randomized controlled phase I/I trial (R10933-10987-COV-2067 study) compared REGN-COV2 antibody with placebo.110 An interim analysis of this study indicated that the combination of casirivimab and imdevimab may have a greater effect in patients who test negative for SARS-CoV-2 serum antibodies at baseline. The proportion of patients who had at least one COVID-19-related medical visit was lower in the casirivimab plus imdevimab group (3%) than in the placebo group (6%).110 Based on the results, the FDA issued EUAs to use casirivimab plus imdevimab in outpatients with mild-to-moderate COVID-19111 (Bila). The authorized dosage for both casirivimab and imdevimab were 1200 mg intravenous (IV) infusion for over 1 h. Present studies have no evidence of the comparison of the casirivimab and imdevimab with bamlanivimab and etesevimab. More details concerning the comparison remain to be determined.

**S protein in SARS-CoV variants.** D614G mutation of S protein was found with increased transmissibility, which played a predominant role early in the COVID-19 pandemic.112,113 However, among vaccinated individuals and patients with COVID-19, this mutation showed a mild effect on neutralizing their sera.114 Recently, several variants of SARS-CoV-2 with increased transmissibility have emerged worldwide, compromising virus control and raising concerns that the unknown and constant mutations might weaken current efforts on combating the pandemic. Therefore, three main SARS-CoV-2 variants that caused the outbreak have been summarized in this study, and whether current available therapy could fight against viral infection sequentially has been illustrated. Moreover, other potential therapies preventing reinfection by new variants are summarized as follows:

The variant B.1.1.7 of SARS-CoV-2 (UK variant), also named as S01Y.V1 or variant of concern 202012.V1, first emerged in England, has caused a surge in COVID-19 cases.115 This variant has been reported to be spread to >50 countries and seems to become virulent in the future.116–118 It has eight S protein mutations except for D614G.119 SARS-CoV-2 B.1.351 (S01Y.V2) and P.1 (S01Y.V3), also termed as South Africa variant and Brazil variant, respectively, were claimed to have more strong infectious ability. These three variants share the N501Y mutation in RBD, which is associated with enhanced transmissibility. B.1.351 and P.1 variants, respectively, harbor 9 and 11 exchanges, including N501Y, E484K, and K417N (B.1.351)/T (P.1) mutations in the RBD. Additionally, B.1.1.7 has >69–70 and 144 deletions and B.1.351 has 242–244 deletions in NTD, both of which could damage the antibodies’ binding sites in NTD.120,121 Although P.1 variant lacks NTD deletions,122 it could also be studied with point mutations in this area, which might harbor similar functional performances. Because majority of mutations are located in the ACE2-binding site (RBD) or the antigenic supersite in NTD,120,121 which are the potential targets of virus nAbs, the efficacy of vaccines and mAb therapies could be impaired by these variants.119 In fact, the susceptibility to therapy-mediated reaction varied between SARS-CoV-2 wild type (WT) and the other three variants. However, previous evidence demonstrated that no major differences were found in the entry kinetics of the virus, efficiency of virus–cell and cell–cell fusion, and stability of the S protein between SARS-CoV-2 WT and variants B.1.1.7, B.1.351, and P.1.123

**Vaccine sera.** As the extensively utilized therapy, vaccines are administered with great expectations in combating with SARS-CoV-2 variants. Indeed, vaccine antigens utilizing the full-length S protein, containing S-mRNA and S-subunit vaccines, have shown different neutralization activity toward the three variants.124–126

Regarding mRNA vaccines, several studies127–129 reported that serum from individuals vaccinated with BNT162b2 and...
mRNA-1273 could efficiently neutralize B.1.1.7 spike protein (SP) in pseudoparticles.\textsuperscript{129,130} Although B.1.1.7 strains presented with additional mutations (N501Y + 69/70-deletion), they could be neutralized robustly by BNT162b2-induced antibodies.\textsuperscript{131} However, B.1.351 and P.1 variants’ neutralization was found to be reduced\textsuperscript{128} significantly in BNT162b2 and mRNA-1273 vaccines. Currently, mRNA-1273.351 has been studied against B.1.351 in phase I clinical trial (NCT04785144). Similar results were presented with Sputnik V Ad26/Ad5 vaccine.\textsuperscript{132} The sera from inoculated participants demonstrated the efficacy of neutralizing B.1.1.7 SP protein and mildly decreased activity in combating only E484K-substituted SP protein.\textsuperscript{133} Inversely, B.1.351 failed to be neutralized by Sputnik V Ad26/Ad5 vaccine. Additionally, both the AZD1222 and NVX-CoV2373 vaccines could provide protection for B.1.1.7 variant.\textsuperscript{134,135} Janssen, Novavax, and AZD1222 vaccines showed a marked reduction in efficacy for B.1.351 variant, whereas the first two still presented over 50% protective efficacy for moderate and severe disease.\textsuperscript{136} However, efficacy of AZD1222 was approximately 10% in fighting with B.1.351-caused mild-to-moderate disease, and no efficacy was demonstrated against severe disease in a phase II trial.\textsuperscript{137,138} The neutralizing geometric mean titers (GMTs) against P.1 variant for AZD1222 showed similarity with those against B.1.1.7 variant and considerable superiority to those against B.1.351 variant.\textsuperscript{136} Apart from these, Ad26.COV2.S vaccine directed mAbs,\textsuperscript{119} which is largely conferred by 144 deletion. B.1.351 resistance largely depends on the R246I and/or 242–244 deletions. All 144 and 242–244 deletions and R246I fall within the supersite of NTD.\textsuperscript{125,126} P.1 does not have NTD deletions but NTD mutations (R190S, D138Y, P26S, T20N, and L18F), which could influence the binding of mAbs. Notably, these EUA mAbs targeting RBD are majorly involved in B.1.351 and P.1 resistance.

Casirivimab (REGN10933) could partially inhibit virus entry of B.1.351 and P.1 variants, in line with the mutations in the antibody-binding site of the S protein. Moreover, the neutralization ability of casirivimab could be severely damaged (773-fold), whereas that of imdevimab was unaffected by B.1.351.\textsuperscript{144} The EUA antibody cocktail (REGN-COV2), combining casirivimab with imdevimab (REGN10987), could restore efficient suppression, manifesting the suitability of this regimen for B.1.351 and P.1 infection. Conversely, another EUA antibody for SARS-CoV-2, bamlanivimab, failed to inhibit entry driven by B.1.351 and P.1 S protein, which is according to the E484K mutation in the antibody-binding region.\textsuperscript{115}

Vaccines can be more beneficial when they utilize immunogens, which produce and enrich RBD-targeted nAbs. It shows more resistance to the variants of SARS-CoV-2 with their multiple RBD-binding models, thus protecting broader spectrum of virus variant. Naturally, RBD-based vaccines increase concerns for researchers. ZF2001, as an RBD-recombinant vaccine, has been studied for its effectiveness against SARS-CoV-2 variants. Huang et al.\textsuperscript{140} evaluated the neutralization activity in ZF2001-induced (n = 12) and BBIBP-CoV (n = 12) serum nAbs against SARS-CoV-2 B.1.351. They found that the variant B.1.351 could not escape the immunity induced by these two vaccines. However, when the GMTs are reduced 1.5–1.6 times, the clinical efficacy of ZF2001 and BBIBP-CoV could also be influenced. Another study conducted by Cao et al.\textsuperscript{127} revealed that ZF2001 vaccines had double tolerant ability for combating SARS-CoV-2 B.1.351 than CoronaVac vaccines in authentic or pseudovirus assays. Notably, half-maximal neutralizing titer (NT50) reduction was found less in the extended three-dose (0/30/140 days) than in the standard three-dose (0/30/60 days) ZF2001 group, which may be attributed to the extra antibody maturity induced by constant hypermutations before the boost of the third dose.\textsuperscript{141} ZF2001 with an extended three dose could motivate enhanced neutralization activity so that it could counter S01Y.V2 utilizing a suitable third-dose boost.

In fact, because various experimental designs of neutralization assays are performed using pseudovirus, comparing the neutralization fold changes among different types of vaccines is difficult. However, the efficacy trend is similar, i.e., B.1.1.7 variant has the least possibility to escape from the neutralization antibodies induced by the licensed or EUA vaccines, followed by P.1 and B.1.351 variants. With the additive effect of E484K and 242–244A, B.1.351 presented with the most significant reduction of neutralization reaction. Moreover, several studies suggested that B.1.351 with full suite of mutations could decrease the immunological surveillance substantially including only three RBD exchanges (N501Y, E484K, and K417N) owing to the non-RBD changes.\textsuperscript{142} Therefore, developing vaccines against B.1.351 should be given the highest priority. Considering that P.1 showed similar RBD exchanges with B.1.351 but with less impaired neutralization, implying no widespread escape presentation, the ancestral/parent strains may protect from P.1 continuously. Currently, RBD-based vaccines are considered ideal for countering potential NTD mutations, especially the vaccines with the third booster shot.\textsuperscript{122} The combination of the variant vaccines and the current vaccines (bivalent vaccines) could also be considered. Before the violent spread of the variants, rapid deployment of WT antigen vaccines may help in putting an end to the pandemic.

**Monoclonal antibodies.** Several researches have illustrated the resistant effect of mAbs on B.1.1.7, B.1.351, and P.1 variants.\textsuperscript{143–145} B.1.1.7 variant is refractory to the neutralization by NTD supersite-directed mAbs,\textsuperscript{119} which is largely conferred by 144 deletion. B.1.351 resistance largely depends on the R246I and/or 242–244 deletions. All 144 and 242–244 deletions and R246I fall within the supersite of NTD.\textsuperscript{125,126} P.1 does not have NTD deletions but NTD mutations (R190S, D138Y, P26S, T20N, and L18F), which could influence the binding of mAbs. Notably, these EUA mAbs targeting RBD are majorly involved in B.1.351 and P.1 resistance. The combination of the variant vaccines and the current vaccines (bivalent vaccines) could also be considered. Before the violent spread of the variants, rapid deployment of WT antigen vaccines may help in putting an end to the pandemic.
MERS, whereas several key points can distinguish them, including the nidovirus RdRp-associated nucleotidyltransferase. However, there is not sufficient evidence to evaluate how this difference affects the effectiveness of nucleotide analog medicines for COVID-19.

Several drugs that inhibit RdRp and have been approved in other infected diseases were considered to be repurposed in COVID-19. Remdesivir, once approved to be used for Ebola virus treatment, is proved to be effective in COVID-19 by targeting Nsp12 and inhibiting the synthesis of viral RNA. It has a 1'-cyano-substituted adenosine nucleotide that mimics and transfers into active RdV-TP in the body. RDV-TP is proposed to inhibit the viral RdRp through nonoligate RNA chain termination. Several large-scale clinical trials have evaluated the safety and efficacy of remdesivir in treating COVID-19. In ACTT-1 trial, remdesivir reduced the time to clinical recovery in patients with severe disease and has improved outcomes in hospitalized patients with moderate COVID-19 compared with standard of care. FDA has approved the use of remdesivir to treat COVID-19 in hospitalized patients (age ≥12 years and weight ≥40 kg). According to the CTGP, remdesivir is recommended in hospitalized patients who need supplemental oxygen (Bila). The main side effects of remdesivir include elevated transaminase levels, gastrointestinal symptoms (e.g., nausea), increased prothrombin time, and hypersensitivity reactions.

Similar to remdesivir, nucleotide analog drugs, including ribavirin and favipiravir, inhibit the transcription of viral RNA by mimicking RNA nucleotide and covalently linking to the replicating RNA. Ribavirin, a guanine analog, is also a type of RdRp inhibitor. It is widely used in hepatitis C and human respiratory viral infections. Its antiviral activity to other coronaviruses makes it a drug candidate for COVID-19 treatment. On the clinicaltrial.gov website, two trials on ribavirin are recruiting, among which one has been completed. The published data have shown that early triple combination of ribavirin, IFNB-1b, and lopinavir/ritonavir was safe and effective in patients with mild-to-moderate COVID-19 compared with lopinavir/ritonavir alone with respect to controlling symptoms, promoting viral shedding, and shortening hospital stay. However, it was a small-scale clinical trial with 127 patients and was not enough to confirm the effect of ribavirin on SARS-CoV-2. Ribavirin causes severe dose-dependent hematologic toxicity. Red blood cells in the human body lack dephosphorylated enzymes. The phosphorylated ribavirin accumulates in red blood cells, resulting in a high concentration, which ultimately changes the fluidity of red blood cell membranes, leading to hemolytic anemia. It also has strong reproductive toxicity that can cause fetal anomalies. Thus, ribavirin was not recommended in COVID-19 treatment. Other RdRp inhibitors are under research, but no positive results have been gained to date. Favipiravir has been approved for the treatment of influenza virus and showed a promise in Ebola virus treatment. On the clinicaltrial.gov. website, 31 clinical trials of favipiravir in COVID-19 are ongoing or completed. However, to date, no clinical results have been presented to support the use of lopinavir/ritonavir or other HIV protease inhibitors in COVID-19. Both the large-scale multicenter clinical trials RECOVERY and Solidarity Trial suggested no preference of favipiravir/ritonavir compared with standard care. The unsatisfactory results of lopinavir/ritonavir against SARS-CoV-2 can be because the protease of SARS-CoV-2 is different from that of retrovirus (the aspartic and chymotrypsin-like protease families, respectively). Additionally, the plasma drug concentration achieved with the typical dose of favipiravir/ritonavir is far below the level required to inhibit SARS-CoV-2 replication. Other antiretroviral drugs were identified to be effective through enzyme activity screening but failed in clinical practice, including darunavir/cobicistat. Based on the abovementioned evidences, CTGP recommends against the use of HIV protease inhibitors, including lopinavir/ritonavir, for the treatment of COVID-19 in hospitalized patients (AII) and nonhospitalized patients (AII).

Despite the failure of protease inhibitors in clinical trials, multiple preclinical researches have continued putting in efforts. At the beginning, structure-based virtual and high-throughput screening was used for drug selection. High-throughput drug screening and in vitro study showed that boceprevir, approved for treating anti-HCV, and GC376, a preclinical inhibitor designed to treat feline infectious peritonitis (corona) virus, can suppress Mpro activity and SARS-CoV-2 in vitro. Zhang et al. synthesized peptidomimetic α-ketoamides, a broad-spectrum inhibitor of the Mpro of β-CoV, α-CoV, and enteroviruses. The concentration for 50% of the maximal effect (EC50) for MERS-CoV in Huh7 cells was 400 µM, and it also had low µM EC50 values for SARS-CoV and enterovirus. Recently, they declared the Mpro X-ray structures. With α-ketoamide as reference, adding the P3–P2 amide into a pyridine ring to enhance the half-period of the compound in serum is also an alternative to improve drug efficacy. Recently, in the BSL-2 laboratory, the cell-based luciferase complementation reporter assay has been established to select SARS-CoV-2 Mpro inhibitors. It can easily distinguish actual Mpro inhibition from cytotoxicity, thereby significantly improving screening efficacy. Five inhibitors, including Z-FA-FMK, boceprevir, calpain inhibitor XII, GRL-0496, and GC376, have been identified through this method. However, these drugs have not been clinically tested.

Antiviral release

The process of viral release usually occurs through three ways: host cell lysis, budding, or exocytosis. Oseltamivir is a produrg against neuraminidase inhibitor, approved for the treatment and prophylaxis of influenza A and B. Mechanistically, the lipophilic side chain of oseltamivir metabolites binds to the hydrophobic pocket of the active site of the viral neuraminidase to impair the functional proteins. Mpro possesses >11 action sites on the pp1ab, and their most recognition sequence is Leu-Gln ↓ (Ser, Ala, Gly) ↓ (marks the cleavage site). Replication would stop without Mpro. Considering the essential functions in the virus and lack of homologous series in host cells, Mpro is believed to be a candidate target to fight against SARS-CoV-2. However, there is no protease inhibitor of Mpro with satisfactory effect to date. Lopinavir/ritonavir, approved to be used in HIV, was thought to inhibit the Mpro but has shown no benefit in clinical practice. Lopinavir and ritonavir are antiretroviral protease inhibitors, which were approved as combination therapy in the treatment of HIV infection. Lopinavir functions as a specific inhibitor of HIV-1 protease that prevents HIV-1 replication in host cells and blocks the infection of HIV-1. The combination of ritonavir decreases the hepatic metabolism of lopinavir and enhances its efficacy. Lopinavir showed inhibition of coronavirus (MERS-CoV and SARS-CoV) replication in in vitro experiments. In the clinicaltrials.gov website, 22 interventional clinical trials of lopinavir/ritonavir in COVID-19 are ongoing or completed. However, to date, no clinical results have been presented to support the use of lopinavir/ritonavir or other HIV protease inhibitors in COVID-19. The unsatisfactory results of lopinavir/ritonavir against SARS-CoV-2 can be because the protease of SARS-CoV-2 is different from that of retrovirus (the aspartic and chymotrypsin-like protease families, respectively). Additionally, the plasma drug concentration achieved with the typical dose of lopinavir/ritonavir is far below the level required to inhibit SARS-CoV-2 replication. Other antiretroviral drugs were identified to be effective through enzyme activity screening but failed in clinical practice, including darunavir/cobicistat. Based on the abovementioned evidences, CTGP recommends against the use of HIV protease inhibitors, including lopinavir/ritonavir, for the treatment of COVID-19 in hospitalized patients (AII) and nonhospitalized patients (AII).

The 3-chymotrypsin-like protease or main protease. 3-chymotrypsin-like protease or main protease (Mpro, Nsp5) is involved in the replication and transcription of viral genes. Mpro, similar to a knife, cuts the viral-translated polyproteins into

SPRINGER NATURE
ability of neuraminidase to cleave sialic acid residues on the surface of the infected host cells. It inhibits the release of progeny virion by budding from the infected cells. 178 Eight clinical trials on oseltamivir and COVID-19 are registered in clinicaltrial.gov, and none of them has been marked as complete. Therefore, the data of oseltamivir in COVID-19 are insufficient.

**TARGET HOST CELL**

As host factors are important regulators of SARS-CoV-2 infection, they are potential targets for antiviral therapy. Hence, the discovery of novel host genes or proteins and related signaling pathways that mediate pathogenesis of COVID-19 is a critical resource that may help us understand the exact biological pathogenesis of this disease based on host factors and may reveal host-directed therapeutic targets against SARS-CoV-2 infection.

Receptors in host cells impact the viral entry

Angiotensin-converting enzyme-2. The ACE2 gene precisely maps to chromosome Xp22 comprising 20 introns and 18 exons, spans 39,98 kb of genomic DNA, generating 6 variants via alternative splicing, 179 and encodes a type I membrane-bound glycoprotein, ACE2. ACE2 is a homolog of ACE. It comprises 805 amino acids and includes a C-terminal transmembrane anchoring region (carboxy-terminal domain), N-terminal signal peptide region, and a conserved HEXXH zinc-binding metalloclopeptase motif (catalytic domain). 180 Although SARS-CoV mainly infects macrophages, pneumocytes, and the lungs, 181 ACE2 expression is not limited to the lungs and involves the extrapulmonary tissues. 182–184 Analysis of the expression level of ACE2 in animal models and the evaluation of the human transcriptome using data from different databases indicated that it is high in the small intestine, kidney, colon, testis, thyroid gland, and heart muscle, 185,186 whereas it is extremely low in the lung, with no expression in the blood cells. 187,188 This explains why people affected by COVID-19 suffer from gastrointestinal dysfunction and kidney problems. 189,190 It has a wide range of biological activities, and the main function is to regulate the renin–angiotensin system (RAS) in several diseases. 180,191,192 Regarding infection with coronaviruses, the virus makes use of the host receptors as a doorway for entry into the host cell. The S proteins of SARS-CoV-2 binding to the human ACE2 for entry into the host cell make the ACE2 a druggable target for COVID-19. 193–195

Being a host receptor, ACE2 is commonly localized on the plasma membrane (mACE2). Its N-terminal comprises the catalytic site protruding from the extracellular environment, with multiple active peptides present in the interstitium as substrates. ACE2 can be hydrolyzed by diverse proteases, including TMPRSS2, a disintegrin and metallopeptase domain-containing protein 10 (ADAM10), and ADAM17. The S1 subunit of the SARS-CoV-2 S protein binds to the ACE2 receptor and then triggers the cleavage of ACE2 by tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM17 at the ectodomain sites, 196 producing a soluble form to maintain its catalytic activity (sACE2). 195 Notably, in both in vitro and in vivo experiments, TACE inhibitors can reduce viral entry, demonstrating their essential role in determining SARS-CoV infectivity and their potential use as targets for antiviral treatments. Meanwhile, ACE2 can be shed from the cell and then released into the circulation by ADAM17 while maintaining its catalytic activity and its ability to bind with SARS-CoV-2. In the context of the COVID-19 pandemic, understanding the mechanisms of ACE2 shedding, sACE2 function, and sACE2 plasma level can contribute to the improvement in therapy and diagnosis to track infection progression. The researchers suggested the use of human recombinant ACE2 (hrACE2) protein to saturate the viral S protein and then restrain SARS-CoV-2 cellular entry. 196 Additionally, the soluble hrACE2 (shrACE2) has attractive physiological characteristics because it can inactivate SARS-CoV-2 present in the extracellular environment. Unlike anti-inflammatory or antiviral therapies, shrACE2 can decrease the binding between mACE2 and SARS-CoV-2 and reduce infectivity. 197 Additionally, shrACE2 can offset the elevation of LDEABK/DEABK and Ang-II preserving lung function. Administration of hrACE2 is well tolerated in healthy subjects, 198 and it has been successfully available in treating patients with ARDS. 199 Moreover, shrACE2 can reduce the infection with SARS-CoV-2 in vitro 200 and the delivery of shrACE2 could decrease protease degradation 201 as has already been demonstrated. APN01 is a fully glycosylated rhACE2 and presents a stable noncovalent homodimer. 202 Although our understanding of the role of endogenous sACE2 in human physiology remains limited, the abovementioned studies have demonstrated that shrACE2 could be an effective drug for the treatment of SARS-CoV-2 infection. Other potential therapeutic strategies, which are targeting ACE2, include blocking the surface ACE2 receptor using anti-ACE2 peptides or antibody. 198 In a recent research, authors used a single-chain antibody fragment (scFv) or antibody to bind ACE2 and block the interaction between the S protein and ACE2. 203 Additionally, as mentioned above, the main function is to regulate the RAS in several diseases. 180,191,192 After viral infection, ACE2 downregulation in organs can disturb the balance between the RAS and ACE2/angiotensin-(1–7)/MAS axis, causing organ injuries. Animal experiments have shown that ACE inhibitor (ACEI) can decrease plasma Ang-II levels and increase the plasma angiotensin (1–7) levels and cardiac ACE2 expression, whereas angiotensin II receptor blockers (ARBs) can increase both Ang-II and angiotensin (1–7) plasma levels as well as ACE2 activity and the cardiac expression. 203 Thus, the available renin inhibitors, angiotensin (1–7) analogs, and ACEIs/ARBs may relieve organ injuries via the blockage of the renin–angiotensin pathway and/or increased angiotensin(1–7) levels. 204 Other animal researches showed that infection with influenza virus in mice or the acute lung injury mediated by SARS-CoV spike could be rescued by ARBs. 205–207 A population-based study indicated that the ARBs and ACEIs significantly reduced the 30-day mortality rate in patients with pneumonia requiring hospitalization. 208 Concerns also exist that ACEIs/ARBs treatment may facilitate SARS-CoV infection and increase the risk of severe/fatal COVID-19 progression by enhancing the ACE2 expression levels in target organs. 209 However, in two large sample studies, ACEIs/ARBs use would not increase SARS-CoV-2 infection. 210 The prospect of ACEIs/ARBs in COVID-19 treatment needs to be validated in future studies.

**TMPRSS2.** TMPRSS2 is located at 21q22.3 on chromosome 21, and its expression is regulated by androgen signaling through multiple androgen receptor elements upstream of the transcription start site of the gene. Moreover, TMPRSS2 is a protease belonging to the type II transmembrane serine protease family that cleaves the influenza virus hemagglutinin molecule of the human airway epithelial cells. 211 It can also cleave the S protein, which is activated by protease and induces virus–membrane fusion on the cell surface. 212–215 The viral hemagglutinin protein binding to ACE2 is the first step in allowing host cell entry. In the second step, hemagglutinin is cleaved, thereby activating internalization. This step depends on the proteases of the host cell, particularly the TMPRSS2. 216 This highlights the conserved and central role of TMPRSS2 in the pathogenesis of COVID-19. An in vitro study demonstrates that the inhibition of the protease activity of TMPRSS2 partially prevents the entry of SARS-CoV-2 into the lung epithelial cells. 15 A research conducted by Shutoku et al. demonstrated that TMPRSS2 may be a key protease for SARS-CoV-2 replication and could enhance SARS-CoV-2 infection. 217 Furthermore, the inhibition of TMPRSS2 activity in the human lung cells by camostat mesylate in vitro was demonstrated to be effective against SARS-CoV-2 infection. 15 Thus, developing TMPRSS2 inhibitor-associated therapeutic drugs is probably a promising
response to the current and new CoVs outbreaks. Moreover, several animal researches indicate that TMPRSS2-knockout mice are protected from disease progression and death after infection with influenza virus. Importantly, in an in vivo study, TMPRSS2-deficient mice were demonstrated to reduce viral replication in the lungs. Furthermore, histopathological and immunohistochemical tests showed that TMPRSS2 expression affected the primary site of infection and the transmission of the virus in the airway with different immunopathologies. Considering the forceful preclinical support of camostat mesylate for SARS-CoV-2 infection, several clinical trials assessing it alone or in combination with HCQ have been initiated in Europe and the United States. Moreover, another TMPRSS2 inhibitor, nafamostat, may be effective against SARS-CoV-2 infection.

Considering the expression of TMPRSS2 that is regulated by androgen signaling, it was found to be highly expressed in the
prostate epithelium. Inhibiting the androgen receptor is an alternative strategy. Before using protease inhibitors or androgen deprivation therapy (ADT) to inhibit the activity of TMPRSS2, understanding the functional polymorphisms of the gene is warranted. Two missense variants (rs12329760; c.589G>A p. Val197Met and rs75603675; c.23G>T p. Gly8Val) within TMPRSS2 have been identified, and their frequencies vary by geography and ancestry. In fact, TMPRSS2 expression on nasal epithelial cells was already found to be higher in Black individuals than in White, Latino, and Asian individuals, which could explain the 2–3 times higher incidence of COVID-19 in Black individuals than in other individuals. The functional polymorphisms of TMPRSS2 should be studied as a priority to identify patients who could greatly benefit from these protease inhibitors or ADT.

Although an aberrant fusion of TMPRSS2 with ERG or other oncogenes, including ETV1, ETV4, and ETV5, is a common trait in prostate cancer, decreasing the TMPRSS2 expression by inhibition of androgen signaling via use of antiandrogens or ADT that are standard therapies for prostate cancer may be a novel approach against SARS-CoV-2 infection. Although the safety and effectiveness of these treatments have been well demonstrated in prostate cancer researches, more preclinical researches are still required to evaluate these novel approaches against SARS-CoV-2 infection.

Serine protease inhibitor might constitute a treatment option through entry blocking by targeting TMPRSS2. Camostat mesylate, a serine protease inhibitor, was developed in Japan and is applied to treat pancreatitis. Approximately 20 clinical trials on camostat mesylate and COVID-19 are registered in clinicaltrial.gov; however, none of them have been completed. Nafamostat, used as an anticoagulant, is also a serine protease inhibitor. Japanese scientists disclosed that nafamostat inhibits SARS-CoV-2 in vitro (EC50 = 22.50 μM) by potently binding to TMPRSS2. Additionally, its ability of fusion inhibition is less than one-tenth of the concentration required by camostat. Thus, nafamostat is also a potential repurposing drug for COVID-19.

Immunomodulatory factors

Studies have demonstrated a dysregulated immune response in patients with severe COVID-19, which may be the main cause of lung injury and multiple organ failure. As mentioned above, viral proteins of SARS-CoV-2 have been demonstrated to play important roles in the innate and adaptive immunity. Discovering the characteristics of immune responses to SARS-CoV-2 infection is fundamental for understanding the pathogenesis of COVID-19 and developing immunological therapies. Several methods to modulate the excessive immune response in patients with COVID-19 have been tested in clinical practices.

Interferons. IFN, which is a key inflammatory cytokine in CoV infections, is regulated by histone marks, controlling viral infection both in vitro and in vivo. Moreover, IFN activation is modulated by epigenetic regulators, including H3K4me3, H3K27me3, and H3K9me2. Furthermore, CoVs have ISG effector functions, are actually associated with histone marks of ISG genes at the promoters, and differ from different viruses. IFNs are mainly used in certain kinds of cancers and hepatitis. Researches showed no benefit of IFN-α/β in patients with severe coronavirus (SARS and MERS). The early triple combination of IFNβ-1b and lopinavir/ritonavir was preferable to lopinavir–ritonavir alone in negative PCR results, thereby relieving clinical symptoms and shortening hospital stay in patients with mild-to-moderate COVID-19. Other clinical trials from Iran and China have obvious bias that can hardly evaluate the efficacy of IFNs. Conversely, IFNs have obvious adverse events, including flu-like symptoms, headaches, gastrointestinal reactions, and rashes. To data, there is insufficient data to evaluate the potential benefits and toxicity risks of IFNs. Thus, CTGP has not commented on the use of IFNs for patients with mild COVID-19 and recommends against its use in severe or critical COVID-19, except in a clinical trial (AllI).

Corticosteroids. Besides inflammatory cytokines, during the cytokine storm, some proinflammatory cytokines (IL-1β, -6, -12, -18, and -33 and TNF-α) are always increased in SARS-CoV infection. Moreover, the incidence of cytokine storm is regulated by the demethylation of IFN-regulated and cytokine genes. Hence, decreasing the plasma level of inflammatory or proinflammatory cytokines epigenetically are potential targets to cure COVID-19. Corticosteroid could decrease the severity of cytokine storm and reduce the mortality of patients with SARS-CoV-2 infection. Dexamethasone is one of the representative drugs of corticosteroids and is mainly used in allergic and autoimmune inflammatory diseases. Based on large, multicenter, randomized, open-label trials, CTGP recommends the use of dexamethasone for certain hospitalized patients with COVID-19. However, this benefit may be offset by adverse effects, including delayed virus clearance and increased risk of secondary infection. In the RECOVERY trial, the use of dexamethasone significantly reduced the 28-day mortality in patients who needed respiratory support or extra oxygen supply. The recommendation dose of dexamethasone is 6 mg daily by oral administration or IV injection or dose equivalencies to other corticosteroids. The duration of dexamethasone treatment should be up to 10 days or until hospital discharge. Adverse events, including hyperglycemia, secondary infections, psychiatric effects, and avascular necrosis, should be closely monitored. Additionally, several small-scale clinical trials evaluated the efficacy of corticosteroids in COVID-19. In the CoDEX study, compared with the standard of care alone, adding dexamethasone increased the days of survival and free from mechanical ventilation days to >28 days in patients with moderate-to-severe ARDS caused by COVID-19. However, some studies have different conclusions. A small trial in France showed that hydrocortisone did not reduce mortality or respiratory support in patients with COVID-19 and ARDS in the ICU compared with those with placebo. However, making conclusions is difficult because it was terminated early. It was noteworthy that, owing to the publication of the RECOVERY study, clinical studies on other corticosteroids were terminated early, resulting in insufficient evaluation of other corticosteroids, including methylprednisolone. However, methylprednisolone has its advantages, including fast-onset time and relatively moderate half-life (12–36 h); thus, it plays an important role in several other diseases with immune disorders in clinical practice. Moreover, in the Metcovid study, methylprednisolone reduced the mortality of patients aged >60 years compared with placebo. This study has deduced that methylprednisolone has potential in patients with COVID-19 who need corticosteroids. Furthermore, other corticosteroids also have their advantages and disadvantages. Thus, alternative glucocorticoids, including prednisone, methylprednisolone, or hydrocortisone, can be used as well, if dexamethasone is not available.

Theoretically, the pathogenic mechanism of COVID-19 is mainly induced by two processes. In the early stage, the disease is driven by the replication of SARS-CoV-2 and later by excessive inflammatory response. Based on this, it is speculated that antiviral drugs should be collaborated with immunomodulatory therapy in the treatment of COVID-19. The safety and efficacy of a combination therapy of immunoregulatory drugs and antiviral agents for COVID-19 have not been studied in prospective randomized clinical trials. Recently, a preprint article reported the effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19. The combination of dexamethasone and remdesivir has a potential, and the optimum time or sequencing of using...
dexamethasone and remdesivir are worth further studying. Moreover, the combination of corticosteroids and other antiviral drugs are worth assessing.

**Anti-inflammatory cytokines.** Other proinflammatory cytokines or receptor inhibitors, including IL-1 and IL-6 receptor inhibitor, showed significant benefit of survival in patients with COVID-19. The IL-1 inhibitor anakinra is a recombinant human IL-1 receptor antagonist. It was approved for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes. Some case reports reported favorable responses in patients with cytokine release syndrome or macrophage activation syndrome, which were thought to be one of the causes of ARDS among patients with COVID-19. A case-control study in Paris suggested a preferential use of anakinra in patients with severe COVID-19 for reducing the need for invasive mechanical ventilation in the ICU and mortality; however, considering the 14% of patients who died within the first 2 days and 43% of patients who reached the composite primary outcome in the control group, this study had obvious bias. Therefore, the use of IL-1 inhibitors is neither recommended nor contraindicated for treating COVID-19.

Tocilizumab and sarilumab are humanized mAbs against IL-6R, mainly used in rheumatoid arthritis as immunosuppressive drugs. The efficacy and safety of IL-6 inhibitors in patients with COVID-19 have been evaluated and have resulted in some controversial findings. A pilot prospective open, single-arm multicenter study on off-label use of tocilizumab involving 63 hospitalized adult patients with severe COVID-19 demonstrated survival improvement (hazard ratio 2.2 95% confidence interval 1.3–6.7, p < 0.001). Toniati et al. reported that patients with severe COVID-19 with ARDS showed rapid, sustained response to tocilizumab. However, these studies were limited because no comparison group has been presented. A systematic review and meta-analysis that enrolled 7 retrospective studies involving 592 adult patients with severe COVID-19, including 240 in the tocilizumab group and 352 in the control group, showed nonsignificant differences between the tocilizumab and control groups. Two large-scale clinical trials, RECOVERY and REMAP-CAP, reported reducing mortality with the use of tocilizumab; however, these trials were also impacted by heterogeneous populations. Because of low-quality evidence, no conclusion has been reached whether tocilizumab should be used in patients with severe COVID-19. But after comprehensive evaluation for the already shown proofs, the CTGp recommended the use of tocilizumab in combination with dexamethasone for hospitalized patients with rapid respiratory decompensation (Bila); however, siltuximab needs further evaluation owing to insufficient clinical data.

Important pathways and inhibitors

Because IFN inhibitor can mitigate the inflammation caused by CoV infections, the IFN antagonism therapy is a promising strategy to inhibit SARS-CoV-2 infection as well as the anti-TNF-α antibody therapy, which remarkably dampens IFN content. Another important immune-related pathway, including NF-kB pathway, and its inhibition pathway SIRT1–AMPK signaling pathway as well as the MAPK and Janus kinase (JAK) pathways are also the therapeutic targets, which are involved in immune response and would be regulated by and can influence epigenetic regulation after SARS-CoV-2 infection.

**JAK signal pathway.** The JAK signal pathway has been recognized as a key driver of several inflammatory diseases. Their anti-inflammatory effect makes them a potential target for treating COVID-19. Nowadays, several JAK inhibitors, including baricitinib, ruxolitinib, and tofacitinib, are available. Baricitinib are approved for the treatment of rheumatoid arthritis. In the ACTT-2 study, patients who received baricitinib achieved clinical recovery later than those who received placebo (median recovery time of 7 vs. 8 days), particularly in patients who required high-flow oxygen or noninvasive ventilation, but no statistically significant difference was found in mortality between the two groups. The side effects of the chronic use of JAK inhibitor are infections, herpes virus reactivation, liver dysfunction, myelosuppression, thrombotic events, and gastrointestinal perforation. Because of the effect of corticosteroids in severe COVID-19, CTGp recommends baricitinib in combination with remdesivir for the treatment of COVID-19 in hospitalized, nonintubated patients who need extra oxygen supply when corticosteroids is not available (Bila).

Ruxolitinib is an oral JAK inhibitor targeting JAK1 and JAK2 and has been approved for the treatment of myelofibrosis, erythrocytosis, and acute graft-against-host disease. It inhibits dose-dependent IL-6-induced signal transducer and activator of transcription factor 3 phosphorylation. A Chinese small-scale randomized clinical trial suggested a radiographic improvement at day 14; however, no difference was observed on discharge time and mortality. Tofacitinib selectively blocks JAK1 and JAK3 and also has moderate activity on JAK2. It is approved by the FDA for the treatment of arthritis and ulcerative colitis and is able to reduce IL-6 level in these patients. Owing to the lack of clinical evidence related to COVID-19, the use of JAK inhibitors other than baricitinib to treat COVID-19 is prohibited, except in clinical trials (Alii).

**Bruton’s tyrosine kinase (BTK).** BTK inhibitors are also considered for use in COVID-19 treatment. BTK, a signaling molecule of cytokine receptor pathways, is important for B cell maturation and function. Acalabrutinib, ibritinib, and zanubrutinib are representatives of BTK inhibitors that are approved in the treatment of certain lymphomas. The attempt for use of BTK inhibitors in COVID-19 treatment is limited in small-scale retrospective clinical studies. Mark et al. found that 10–14 days of acalabrutinib treatment improved the oxygenation of patients with COVID-19 without discernable toxicity. Steven et al. demonstrated that ibritinib could prevent lung injury of patients with COVID-19. However, data of these drugs is insufficient to evaluate the efficacy and safety in treating COVID-19. Hence, BTK inhibitors are recommended against COVID-19, except in a clinical trial (Alii).

Although the existing drugs theoretically target the progression of invasion, replication, and release of virus or excessive immune response, only remdesivir, dexamethasone (baricitinib, if dexamethasone cannot be used), and tocilizumab are recommended for use in certain patients with COVID-19 (Table 2). However, their efficacy was unsatisfactory owing to multiple reasons, including low effective concentration, different binding sites, and uncertain mechanism. Our hopes rely on promising potential targets with increasing information on the structure and mechanism of SARS-CoV-2. In the next part, these potential targets will be discussed.

**PROMISING POTENTIAL TARGETS**

In this section, the current state of most promising druggable targets of SARS-CoV-2 was attempted to be summarized based on preclinical categories with the assessment of the advancement of each druggable target. Notably, the targets covered in this section do not include all the potential SARS-CoV-2 targets.

** Spike glycoprotein**

**HR1 and HR2.** Fusion inhibitors have been demonstrated to have a significant potential for both prophylaxis and treatment of viral infections. HR1 and HR2 are considered to display typical α-helical structure, which primarily exert their effect on membrane fusion by forming 6-HB. HR1 and HR2 in SARS-CoV-2 exhibits 92.6 and 100% identity with those in SARS-CoV, respectively. Zhu et al.
analyzed the thermostability and secondary structure of SARS-CoV-2 HR1. They indicated that SARS-CoV-2 HR1 had higher melting temperature (48 vs. 40°C) and α-helical content (66 vs. 41%) than SARS-CoV HR1. Moreover, the binding of HR1 and HR2 showed more stability in SARS-CoV-2 than in SARS-CoV. Cumulatively, a more powerful HR1 and HR2 interaction might exist in SARS-CoV-2, thereby significantly determining its superior fusogenic specialty than SARS-CoV.

Currently, recombinant HR1/HR2 peptides have been reported to block the formation of 6-HB and restrain the fusion of membrane. Existing peptides originated from HR2 include IPB01 and EK1. They could inhibit HR2 to bind with HR1 and thus form 6-HB.282,283 Furthermore, several studies have developed a novel recombinant HR2 peptide with the additional attachment of cholesterol groups to carboxy-terminal of HR2, containing IPB02 and EK1C2.281,282 The previous evidence that lipid conjugation could enhance antiviral ability and intracellular stability supports the aforementioned strategies.284–286 The resultant lipopeptides are considered to preferentially interact with the cell and virus membranes, therefore improving the inhibitors’ concentrations at the virus fusion site. More studies on compounds targeting HR should be encouraged owing to the wide reactivity displayed in CoV strains.287 Most recently, Kandeel et al. assessed that some novel peptides against SARS-CoV-2 fusion by targeting HR2, peptide #2, and its analogs showed their potent inhibition of viral activity and lack of cytotoxicity. These peptides provide an attractive avenue for the development of new therapeutic agents against SARS-CoV-2.288–290 Except for the recombinant peptides, nanoparticle vaccine containing HR has been engineered to evaluate its response in the transgenic hACE2 mice model.289 Ma et al. designed a RBD-HR ferritin nanoparticle vaccine and found that it could reduce the substantial number of HR-specific antibodies. Additionally, nAbs elicited by HR antigen could exert positive effects on the cross-protection of other CoVs. Therefore, in the future, HR should be considered to access and develop broad-range vaccines. However, mutations have also been found in this region. Oliva et al.290 analyzed 415,673 complete S protein sequences and identified all the mutations occurring on the HR1 fusion core. They found that D936Y is the most frequent mutation in the HR1 fusion core. Further study has demonstrated that the infectivity significantly decreased compared with the Wuhan reference strain when it was the only variant. However, it has more infectivity when associated with the D614G mutation than the only D614G variant.290 Thus, the structural effect of the D936Y variant may still need more researches to identify its potential role in the SARS-CoV-2 virulence. More importantly, long-term monitoring and management of mutations in HR are warranted.

Furin cleavage site. The furin cleavage site plays a significant role in the pathogenesis and transmission of SARS-CoV-2. The furin cleavage site is on the S1/S2 boundary of S protein in novel coronavirus, including P681, R682, R683, and A684 (PRRA) four residues.7 The polybasic furin cleavage site is unique in SARS-CoV-2 rather than in other CoVs. First, S protein proteolytic activation needs furin proteases, the expression of which is omnipresent in human cells. This could result in extensive pathogenesis and tissue tropism in SARS-CoV-2. Moreover, Johnson et al.291 developed a SARS-CoV-2 variant without the furin cleavage spot in the S protein. They found that, compared with the WT virus, the variant decreased the processing and replication of S protein in Vero E6 cells and Calu3 human respiratory cells, respectively. Additionally, Peacock et al. found that the infectivity decreased when SARS-CoV-2 lacked the furin cleavage site and was not transmitted to cohoused sentinel animals compared with the WT virus. Moreover, they identified the selective advantages of the furin cleavage site in the lung and primary human airway epithelial cells depending on the expression of TMPRSS2. These data demonstrated that the furin cleavage site on S protein may play an important role in the high transmissibility and infectivity290 of SARS-CoV-2. Further study has demonstrated that the lack of furin cleavage site attenuated pathogenesis of the virus both in hamster and K18-hACE2 transgenic mouse models.290 Moreover, this mutation offered protection against rechallenge with the parentl virus. Together, these data confirmed the important role of the furin cleavage site in the infection and transmission of SARS-CoV-2 and highlighted the significance of this special region in the development of novel therapeutic strategies against SARS-CoV-2 infection.

M and E proteins. M and E proteins are both transmembrane glycoproteins containing 220–260 and 76–109 amino acids in SARS-CoV-2, respectively.290 The M and E proteins exert important effects in regulating the assembly of the virion. M and E proteins possess sequences of trafficking signal and accumulate in the ER. These proteins efficiently combine with the ribonucleoprotein complex for the budding and maturation of new virion particles.290 SARS-CoV-2 M and E proteins share >90% sequence identity with the SARS-CoV homologs. The current model showed that M protein could interact with S, E, and N proteins to induce membrane curvature during the budding of virion.290 Additionally, M protein of the SARS-CoV residues L218 and L219 are essential for N packaging.291 It has been reported that M protein could induce strong humoral responses,292 apoptosis,293 and IFN-β activation.300 Liu et al.294 identified the antigenic epitopes of SARS-CoV M protein in the TM region. Therefore, M protein is a potential immunogen in therapy applications. Additionally, Tsoi et al. reported that the C-terminal domain (CTD) of M protein could block the interaction of critical protein kinases (PKD1 and PKB) in impeding the apoptosis process and releasing caspas 8 and 9, ultimately resulting in cell apoptosis and death.295 Furthermore, M protein is associated with IFN-β activation by a Toll-like-receptor-related tumor necrosis factor receptor-associated factor 3 (TRAF3). Moreover, Fu et al.296 discovered that M protein participates in the innate immune response pathways by interacting with the central adapter proteins MAVS. This interaction attenuated the innate antiviral response through impaired MAVS aggregation and decreased its recruitment of downstream TBK1, TRAF3, and IRF3. These data revealed a mechanism that evades the innate immune response and have demonstrated the potential of M protein as a therapeutic target for the treatment of SARS-CoV-2 infection.

In contrast to M protein, the E protein might also be a promising target for the development of novel agents against SARS-CoV-2. It is the smallest of the major structural proteins and plays critical roles in assembly, budding, and envelope formation of viruses.302 Apart from the important role which E protein plays in the replication cycle of SARS-CoV-2, recently, the nuclear magnetic resonance (NMR) structure of E protein in SARS-CoV-2 showed a pentameric helix bundle around a central cationic pore with hydrophilicity.203,304 Thus, the E protein could work as the ion-channeling viroporin.305 The ion channels result in membrane potential loss and inflammasome activation. Additionally, the interaction of host connection-related proteins (Lin Seven 1/PALS1 and syntenin) and the last four amino acids (DLLV) in E protein might promote the dissemination of virus,295,306 which is proposed to be the cause of inducing the cytokine storm together with E protein’s viroporin property. Thus, E protein also majorly affects host inflammation response. It forms a structurally robust but bipartite channel and can interact with drugs, ions, and other viral and host proteins semi-independently through its N- and C-terminal halves based on the NMR structure analysis. Thus, the E inhibitors have been considered optimal antiviral drugs against SARS-CoV-2.303 Additionally, recombiant coronavirus without E protein has presented decreased virus titers, damaged...
virus maturation, and attenuated virus propagation and thus has been expected to be a promising vaccine candidate. It is noteworthy that Rahman et al. explored only 1.2% mutant strains undergoing complete E protein sequences, highlighting high conservatism (98.8%) of the E protein of SARS-CoV-2. Their results demonstrated that the E protein evolved slowly compared with other structural proteins. The potential of the E protein has been highlighted as a promising target for both the prophylaxis and treatment of SARS-CoV-2 infection.

N protein

The N protein is the most abundant viral structural protein in virion or in vivo and is also a strong immunogen. Current evidence indicated that a therapy targeting membraneless organelles or host cell kinases to modulate N protein could be feasible strategies to fight SARS-CoV-2. The N protein is known to be involved in the packaging of the virus. Based on accumulated evidence, Cascarina et al. proposed that the N protein of SARS-CoV-2 harnesses the capacity of forming or joining biomolecular condensates to disassemble stress granules and improve virus replication or protein translation. Additionally, N protein facilitates virion budding at a proper orientation on the perinuclear, nuclear, endosomal, or plasma membranes, resulting in viral particle release. Moreover, two druggable sites were found in both NTD and CTD. In NTD, site 1 included P162, T135, Q83, and Q70-N75. Site 2 included S176, A173, L167, T165, and L159-P162. In CTD, site 1 was located on the central four-stranded β-sheet, whereas site 2 was close to the C-terminal α-helices. However, most recently, Rahman et al. observed that the N protein of SARS-CoV-2 virus presented higher mutation rate than MERS and SARS-CoV. This situation may challenge the critical role of E protein in the development of vaccines and therapeutics. Therefore, continuous monitoring is required to handle the ongoing mutations of the N protein.

Papain-like protease

The cysteine proteases encoded by coronaviruses are papain-like protease (PLpro, Nsp3). They contribute to the activities of pp1a and pp1ab. The other vital function of PLpro is reducing host immune response power by downregulating crucial signaling molecules such as NF-κB. SARS-CoV-2 PLpro and SARS-CoV PLpro share 83% similarity, whereas the host substrate preferences are different between them: SCoV2-PLpro and SCoV-PLpro mainly cleave the ubiquitin-like ISG15 protein and ubiquitin chain, respectively. The crystal structure showed that SARS-CoV-2 PLpro has high affinity and specificity with ISG15 and modulate the cleavage of ISG15 via combination with IRF3 and reducing type I IFN effects during viral invasion, thus influencing host immune responses (Fig. 4).

Based on the biochemical, structural, and functional studies, new inhibitors against SARS-CoV-2 PLpro have been investigated. Previously, some inhibitors specific against SARS-CoV PLpro were identified. However, none of these inhibitors progressed to clinical usage for SARS-CoV or SARS-CoV-2. Scientists had screened 3727 approved drugs and compounds for repurposing usage in COVID-19 and found no compounds inhibiting PLpro consistently. A recent study identified seven crystal structures that can recognize specific ligand and interact with PLpro and were proved to inhibit SARS-CoV-2 replication in vitro. Unfortunately, these drugs have not been tested in vivo or in clinic. Thus, to date, no certain drugs have been found to target PLpro that can be used in COVID-19; however, recent research could provide some insights for further drug designing. Remarkably, SARS-CoV PLpro has been thought to possess IFN-antagonizing activities. Some other Nsp5s, including SARS-CoV-2 Nsp13, Nsp14, and Nsp15, also showed an ability to inhibit the production of IFN and IFN signaling, which might also affect immune reaction during the process of SARS-CoV-2 infection.

Cathepsin L

CatL is considered a promising candidate against SARS-CoV-2 infection. CatL, a key human endosomal cysteine protease, cleaves the virus S1 subunit on spike glycoprotein at an appropriate acidic pH and facilitates the entry of SARS2-CoV2 into the host cell. Compared with healthy individuals, the circulating level of CatL is markedly higher in patients with SARS-CoV-2 infection and is associated with the status and severity of infection. SARS-CoV-2 infection has been found to upregulate CTSL expression and enzyme activity both in vivo and in vitro. In turn, the overexpression and knockdown in vitro and the use of CatL inhibitor in vivo in mice further confirmed the promotion of CatL to ensure coronavirus entry. Meanwhile, CatL has been demonstrated to not only suppress viral entry but also to interrupt the life cycle of the virus. Additionally, a majority of available CatL irreversible or reversible inhibitors have been successfully synthesized. Amantadine, an antivirus drug, is used and licensed to treat influenza. Amantadine markedly suppresses the SARS-CoV-2 via inhibiting the expression and enzyme activity of CatL nearly without cytotoxicity. X-ray crystal structures of Mpro complex showed that the calpain inhibitors II and XII are active against CatL. Heparin has been observed to exert an antiviral response during SARS-CoV-2 infection, which might be associated with impaired S1/S2 proteolytic activity via inhibition of CatL activity. Teicoplanin can prevent the S protein cleavage by inhibiting CatL activity. Az peptide nitriles exert strong inhibition toward CatL activity. The combination of Mpro and CatL inhibitors is a potent strategy for broadening the therapeutic target spectrum for SARS-CoV-2.

CD147

Based on the elimination of replication or transcription of viruses and reduced immune effects, CD147 is speculated to be a candidate drug to relieve SARS-CoV-2 infection. CD147 has multiple functions in tumor development, plasmodium invasion, and bacterial and viral infection. CD147 binds to CD147-SP and has been identified as a novel host receptor of SARS-CoV-2 on host cells. Notably, CD147 and ACE2 may be two complementary receptors of SARS-CoV-2. CD147 mediates the increase in the levels of proinflammatory cytokines (i.e., TNF-α, MCP-1, IL-6, and INF-γ), thereby activating immune response widely and inducing tissue damage. Although a Chinese clinical trial in phase II, named “Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia” (ClinicalTrials.gov Identifier: NCT04275245), is currently ongoing to inhibit SARS-CoV-2 S protein binding via suppressing the expression of CD147 protein using Meplazumab, the main researches targeting CD147 are still in the preclinical stage. Melatonin can not only strongly protect cells from oxidative damage as hydroxyl radical scavenger but also can modulate the immune system by balancing the inflammation and anti-inflammation effects through a CD147-SP. Hence, melatonin exerts an antiviral effect by reducing the CD147 levels. Considering the double immunomodulatory effects of CD147, the use of CD147 suppressor in combination with other antiviral drugs could benefit patients by improving the efficacy of anti-SARS-CoV-2 effect and preventing the potential negative side effects. Remarkably, a novel human CD147 NOD-scid IL2Rgamma null (NSG) transgenic mouse model has been successfully developed by Badeti et al. The hCD147Tg-NSG mouse model may promote the speed of drug development that targets CD147.
| Drug            | Current use | Target                          | Potential target                                      | Recommendation                  |
|-----------------|-------------|---------------------------------|-------------------------------------------------------|---------------------------------|
| **Antivirus**   |             |                                 |                                                       |                                 |
| Umifenovir      | Influenza   | Prevents fusion of viral and membrane | Nsp7/Nsp8 complex, Nsp14, Nsp15, E-channel, or Spike | Not mentioned                   |
| Nelfinavir      | HIV         | Protease inhibitor               | Spike (S) protein                                      |                                 |
| Aloxistatin     | Nervous system disease | Cysteine protease inhibitor       | Cathepsin L                                            |                                 |
| Camostat mesylate | Pancreatitis | Serine protease inhibitor        | TMPRSS2                                                |                                 |
| Nelﬁnavir      | HIV         | Protease inhibitor               | Spike (S) protein                                      |                                 |
| Camostat mesylate | Pancreatitis | Serine protease inhibitor        | TMPRSS2                                                |                                 |
| Chloroquine     | Anti-malarial|                                 | ACE2, pH, PLpro                                        | Recommend against               |
| Hydroxychloroquine | Autoimmune diseases |                                 |                                                       |                                 |
| **Antireplication** |             |                                 |                                                       |                                 |
| Lopinavir/ritonavir | HIV        | Protease inhibitor               | 3CLpro, Nsp3c, PLpro, E-channel, Spike proteins       | Recommend against (AI)          |
| Darunavir/Cobicistat | HIV        | Protease inhibitor               | 3CLpro, Nsp3c, PLpro, E-channel, Spike proteins       | Recommend against (AI)          |
| Remdesivir      | Ebola virus | RNA-dependent RNA synthetase     | Nsp3b, RdRp, E-channel, TMPRSS2                       | Recommends (BIIa)              |
| Ribavirin       | HCV, RSV    |                                 | PLpro                                                  | Not mentioned                   |
| Favipiravir     | Influenza virus |                                 | RdRp                                                   |                                 |
| **Anti-release** |             |                                 |                                                       |                                 |
| Oseltamivir     | Influenza A and B | Neuraminidase                  | 3CLpro                                                | Not mentioned                   |
| **Immunomodulation** |           |                                 |                                                       |                                 |
| Dexamethasone   | Allergic or autoimmune disease | Glucocorticoid receptor agonist | Different recommends in different situations          |                                 |
| **Corticosteroids** |           |                                 |                                                       |                                 |
| **Anti-cytokine interventions** |           |                                 |                                                       |                                 |
| Anakinra        | Rheumatoid arthritis and cryopyrin-associated periodic syndromes | IL-1R | Neither recommend nor against |                                 |
| Tocilizumab     | Rheumatoid arthritis | IL-6R                         | Recommend (BIIa)                                       |                                 |
| Sarilumab       |             |                                 | Not mentioned                                          |                                 |
| **Kinase inhibitors** |           |                                 |                                                       |                                 |
| Baricitinib     | Rheumatoid arthritis | JAK1, JAK2, gp130                | Recommend in combination with remdesivir if dexamethasone cannot be used (BIIa) |                                 |
| Ruxolitinib     | Myelofibrosis | JAK1, JAK2                        | Recommend against                                       |                                 |
| Tofacitinib     | Psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis | JAK1, JAK3             | Recommend against                                       |                                 |
| **Bruton’s tyrosine kinase inhibitors** |           |                                 |                                                       |                                 |
| Acalabrutinib   | B cell malignancies | BTK                          | Immune response of macrophage activation | Recommend against               |
| Ibrutinib       | B cell malignancies, chronic graft-vs.-host disease in recipients of stem cell transplantation | JAK1, JAK2 | Recommend against                                       |                                 |
| Zanubrutinib    | Mantle cell lymphoma |                                 |                                                       |                                 |
| **IFNs**        |             |                                 |                                                       |                                 |
| **IVIG**        |             |                                 |                                                       |                                 |

*IFN interferon, IVIG intravenous immunoglobulin, HIV human immunodeficiency virus, HCV hepatitis C virus, RSV respiratory fusion virus, IL interleukin, JAK Janus kinase, gp glycoprotein, BTK Bruton’s tyrosine kinase, TMPRSS2 transmembrane protease/serine subfamily member 2, ACE2 angiotensin-converting enzyme-2, 3CLpro 3-chymotrypsin-like protease, RdRp RNA-dependent RNA polymerase, PLpro papain-like cysteine protease, Nsp non-structure protein, pH potential of hydrogen*
High mobility group box 1 (HMGB1) is a highly conserved and multifunctional protein both inside and outside of the cells. In the nucleus, HMGB1 bends DNA as an architectural chromatin-binding factor and regulates DNA replication, transcription, recombination, and repair. Under stressful conditions, HMGB1 is transferred to the cytoplasm and is secreted extracellularly. Extracellular HMGB1 acts as a crucial member of Damage-Associated Molecular Patterns (DAMPS). On the cell surface, HMGB1 binds to classic receptor for advanced glycation end products (RAGE) and Toll-like receptors (TLRs) 2/4/9 and then transmits danger signals to surrounding cells, thereby activating downstream signals and mediating inflammation to infection response. Severe COVID-19 is considered to involve lethal hyperinflammation with cytokine storm syndromes to resist the virus. HMGB1 plays a vital role in the inflammatory response of COVID-19. The levels of serum HMGB1 in patients with severe COVID-19 obviously increased. The significantly elevated levels of serum HMGB1 correlated with the cytokine storm and high mortality of patients with COVID-19, indicating its potential as a predictor of clinical outcome. Pathologically, exogenous HMGB1 promotes the expression of ACE2, the SARS-CoV-2 entry receptor, in cultured lung epithelial cells via RAGE or AKT-dependent manner. The regulation of HMGB1 on ACE2 expression is vital for the entry of SARS-CoV-2, SARS-CoV-1, and NL63, thus affecting the susceptibility to SARS-CoV-2. Thus, HMGB1 is a potential biomarker and therapy target for COVID-19. Based on the changes and direct pathological effects of HMGB1 in COVID-19, genetic inhibitors and pharmacological drugs are explored in the experiments. Genetically, small interfering RNA-mediated depletion of AGER can reduce the HMGB1-induced ACE2 mRNA expression of the lung epithelial cells. Meanwhile, the pharmacological inhibition of HMGB1–AGER pathway limits ACE2 expression in vitro.

Glycyrrhizin, also referred to as glycyrrhizic acid (GLR), is a natural product, mainly isolated from the roots of *Glycyrrhiza glabra* plants. GLR has anti-inflammatory activity against SARS-associated human coronaviruses. At the intracellular and circulating levels, GLR can trap HMGB1 protein and suppress the alarming signals of HMGB1. Additionally, S-RBD and ORF3a of SARS-CoV-2 can upregulate HMGB1 levels as proinflammatory mediators. GLR can attenuate the expression of S-RBD and ORF3a of SARS-CoV-2 in lung cells. Importantly, GLR can safely inhibit SARS-CoV-2 replication at high doses. GLR was previously demonstrated as the most active compound in SARS-CoV. Considering the dual functions of GLR to suppress virus replication and decrease proinflammatory mediators, it should be assessed for use in the treatment of SARS-CoV-2 infection. Moreover, GLR reduces the ACE2 mRNA expression of lung cells in vitro. These encouraging evidences suggest that HMGB1 inhibitors are similarly promising drug candidates for the treatment of patients with COVID-19.

**CONCLUSIONS AND PERSPECTIVES**

Since the influenza pandemic of 1918, the COVID-19 pandemic becomes the greatest global crisis worldwide. Scientists have been making enormous efforts to understand the pathogenesis of COVID-19 and to find methods to fight against the SARS-CoV-2. First, they focus on the pathogenic viral proteins based on pervious experiences with SARS-CoV and MERS-CoV because they all belong to the same genus and share some common characteristics of viral proteins. Hence, repurposing drugs might be the optimal choice, which can extremely shorten the time of drug development because their efficacy and safety have been already clinically demonstrated. However, the results of repurposing drugs are almost a disappointment. Thus, some important issues have emerged: whether these old drugs are really shortcuts...
or just distract our attention? Although the main structures of the main viral pathogenic proteins are similar, there is some variation among them: What are these specific differences? Are these differences the key factors that would affect treatment outcomes? Furthermore, how about the regulatory mechanisms of COVID-19 based on host factors? To answer the abovementioned questions, a comprehensive review was further conducted on the current advancements of the emerging interventional strategies and potential targets based on “target virus” and “target host” categories. Regarding SARS-CoV-2, its structural proteins, especially S protein, are still the most promising direct antiviral targets, and the specific details of their crystal structures may play important roles in SARS-CoV-2 replication cycle, even more important than the common structures among the different coronavirus, and may determine the outcomes of the antiviral strategies. Some viral Nsp5s are vital both in the virus replication and virus–host interactions, which may be indirect targets for the antiviral therapies. Hence, understanding the exact special structures of viral proteins and biological pathogenesis of this disease may reveal novel therapeutic targets against COVID-19.

However, with a minor achievement of potential targets/emerging drugs in combating COVID-19, we have to admit that most targets or new drugs were a failure in the preclinical trials. Although a small number of new drugs were privileged to enter clinical trials, majority of them also failed miserably in phase III clinical trials, including vaccines, which should be reconsidered by researchers (Fig. 7). This is the gap between potential targets/new drug discovery and clinical translation. To make a breakthrough in the coming battle with SARS-CoV-2, several approaches should be considered to cover the gap: concentrating on the most potential druggable targets other than casting a wide net in the future drug development, strengthening cooperation among multiple disciplines, and the last but not the least, long-term monitoring of virus mutations are must. The battle between humanity and SARS-CoV-2 has been stalled for >1 year. Despite tremendous efforts by scientists, there is still a long way to go.

ACKNOWLEDGEMENTS
We would like to apologize to those researchers whose related work we were not able to cite in this review.

AUTHOR CONTRIBUTIONS
Y.-W.Z., Y.X., L.-S.T., D.P., collected and analyzed the data. Y.-J.Z., and L.T. conceived and drafted the paper. Y.Z. drew the figures. J.-Y.L., and X.-L.M. provided valuable discussion and revised the paper.

ADDITIONAL INFORMATION
The online version contains supplementary material available at https://doi.org/10.1038/s41392-021-00733-x.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
2. Bzikov, B. & Bzikov, A. Maximum incubation period for COVID-19 infection: do we need to rethink the 14-day quarantine policy? Travel Med. Infect. Dis. 40, 101976 (2021).
3. Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368, 489–493 (2020).
4. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
5. Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 382, 970–971 (2020).
6. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhnan, China. JAMA 323, 1061–1069 (2020).
7. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
8. Sohail, M. S., Ahmed, S. F., Quadeer, A. A. & McKay, M. R. In silico T cell epitope identification for SARS-CoV-2: progress and perspectives. Adv. Drug Deliv. Rev. 171, 29–47 (2021).
9. Sinivasan, S. et al. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses 12, 360 (2020).
10. Brian, D. A. & Baric, R. S. Coronavirus genome structure and replication. Curr. Top. Microbiol. Immunol. 287, 1–30 (2005).
11. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
12. Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116 (2019).
13. Heald-Sargent, T. & Gallagher, T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 4, 557–580 (2012).
14. Madu, I. G., Roth, S. L., Belouzard, S. & Whittaker, G. R. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J. Virol. 83, 7411–7421 (2009).
15. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
16. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
17. Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–450 (2009).
18. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
19. Woodby, B., Arnold, M. M. & Valacchi, G. SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: what is the connection? Ann. NY Acad. Sci. 1486, 15–38 (2021).
20. Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100–1115 (2020).
21. Asselah, T., Durantel, D., Pasmant, E., Lass G. & Schinazi, R. F. COVID-19: Discovery, diagnostics and drug development. J. Hepatol. 74, 168–184 (2021).
22. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).
23. Beacon, T. H., Su, R. C., Lakowski, T. M., Delcave, G. P. & Davies, J. R. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics. IUBMB life 72, 2331–2354 (2020).
24. Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).
25. Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020).
26. Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 71, 2027–2034 (2020).
27. Frierman, M., Ratia, K., Johnston, R. E., Mesecar, A. D. & Baric, R. S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 83, 6689–6705 (2009).
28. Devaraj, S. G. et al. Regulation of IRF3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282, 32208–32221 (2007).
29. Bailey-Ellkin, B. A. et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 289, 34667–34682 (2014).
30. Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657–662 (2020).
31. Liu, X. et al. Autophagy induced by DAMPs facilitates the inflammation response in lungs undergoing ischemia-reperfusion injury through promoting TRAF6 ubiquitination. Cell Death Differ. 24, 683–693 (2017).
32. Ratajczak, M. Z. et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45(-) precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome. Stem Cell Rev. Rep. 17, 266–277 (2021).
33. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).
34. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).

35. Murakami, T. et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl Acad. Sci. USA 109, 11282–11287 (2012).

36. Bouayad, A. Innate immune evasion by SARS-CoV-2: comparison with SARS-CoV. PLoS Pathog. 18, e1008468 (2022).

37. Berthelot, J. M., Lioret, F., Maquars, Y. & Sibilia, J. Lymphocyte changes in severe COVID-19: delayed over-activation of STING? Front. Immunol. 11, 607069 (2020).

38. Mazzoni, A. et al. Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur. J. Immunol. 50, 2013–2024 (2020).

39. Kroemer, M. et al. COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity. J. Infect. 82, 282–327 (2021).

40. Rydzynski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996.e19–1012.e19 (2020).

41. Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315–320 (2021).

42. Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827 (2020).

43. Kusnadi, A. et al. Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8(+) T cells. Preprint at bioRxiv https://doi.org/10.1101/2020.07.09.194027 (2020).

44. Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. J. Med. Virol. 93, 491–498 (2021).

45. Kroemer, M. et al. COVID-19 patients display a distinct SARS-CoV-2 specific T-cell responses according to disease severity. J. Infect. 82, 282–327 (2021).

46. Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in convalescent individuals. Nature 584, 437–442 (2020).

47. Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040 (2020).

48. Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potent drugs by computational methods. Acta Pharm. Sin. B 10, 766–788 (2020).

49. Blajing, A., Poljak, S. J. & Pécher, E. L. Arbidol as a broad-spectrum antiviral: an update. Antivir. Res. 107, 84–94 (2014).

50. Deng, L. et al. Arbidol combined with LOPVr versus LOPVr alone against coronavirus disease 2019: a retrospective cohort study. J. Infect. 81, 61–65 (2020).

51. Huang, D. et al. Efficacy of an rAd26 and rAd5 vector-based COVID-19 vaccine in mice and monkeys is superior to that of ChAdOx1 nCoV-19. Cell 182, 101–102.e4 (2020).

52. Pai, V. B. & Nahata, M. C. Neofinnavir mesylate: a prostate inhibitor. Ann. Pharmacother. 33, 325–339 (1999).

53. Musarrat, F. et al. The anti-HIV drug nefinnavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J. Med. Virol. 92, 2087–2095 (2020).

54. Kuo, M. et al. Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. Viruses 13, 651 (2021).

55. Al-Bari, M. A. A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol. Res. Perspect. 5, e00293 (2017).

56. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell Res. 30, 269–271 (2020).

57. Vincent, M. J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).

58. Singh, A. K., Singh, A., Shaikh, A., Singh, S. & Misra, A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab. Syndr. 14, 241–246 (2020).

59. Horby, P. et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 383, 2030–2040 (2020).

60. Cavalanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N. Engl. J. Med. 383, 2041–2052 (2020).

61. Geleris, J. et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382, 2411–2418 (2020).

62. Rosenberg, E. S. et al. Association of treatment with hydroxychloroquine or azithromycin in in-hospital mortality in patients with COVID-19 in New York State. JAMA 323, 2493–2502 (2020).

63. FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (2020).
(AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).
94. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
95. An, Y. et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice against SARS-CoV-2 infection. Preprint at bioRxiv https://doi.org/10.1101/2021.03.11.434928 (2021).
96. Yang, S. et al. Immunogenicity and safety of a recombinant tandem-repeat dimeric RBD protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. https://doi.org/10.1016/s1473-3099(21)00074-y (2021).
97. Whitworth, H. S. et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine 38, 1302–1314 (2020).
98. Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479–488 (2020).
99. Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).
100. WHO. WHO target product profiles for COVID-19 vaccines. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines (2020).
101. Lundgren, J. D. et al. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N. Engl. J. Med. 384, 905–914 (2021).
102. Casadevall, A., Joyner, M. J. & Pirofski, L. A. Neutralizing antibody LY-CoV555 for outpatient Covid-19. N. Engl. J. Med. 384, 189 (2021).
103. Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2021).
104. FDA. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for COVID-19. JAMA 325, 495–500 (2021).
105. Gottlieb, R. L. et al. Effect of Bamlanivimab as monotherapy or in combination with etesevimab for COVID-19. N. Engl. J. Med. 385, 2776–2786 (2021).
106. An, Y. et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates. Preprint at bioRxiv https://doi.org/10.1101/2021.03.11.434928 (2021).
107. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating SARS-CoV-2 variants. Nature 592, 616–622 (2021).
108. Muik, A. et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 371, 1152–1153 (2021).
109. Zhu, D. et al. Evidence of escape of SARS-CoV-2 B.1.351 from natural and vaccine-induced sera. Cell 184, 2348.e6–2361.e6 (2021).
110. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
111. Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike viruses. Cell Host Microbe 29, 529–539.e523 (2021).
112. Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2212.e2207 (2021).
113. Xie, X. et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620–621 (2021).
114. Ikegame, S. et al. Qualitatively distinct modes of Sputnik V vaccine neutralization by SARS-CoV-2 spike virus-escape variants. Preprint at medRxiv https://doi.org/10.1101/2021.03.11.434928 (2021).
115. Ikegame, S. et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat. Commun. 12, 4598 (2021).
116. Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397, 1351–1362 (2021).
117. Mahase, E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 372, n296 (2021).
118. Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2393.e9–2954.e9 (2021).
119. Phillips, N., Cyranowski, D. & Mallapaty, S. A leading coronavirus vaccine trial is on hold: scientists react. Nature https://doi.org/10.1038/d41586-020-02594-w (2020).
120. Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature 590, 17 (2021).
121. Solfosori, L. et al. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP. J. Exp. Med. 218, e20202756 (2020).
122. Huang, B. et al. Serum sample neutralisation of BBIBP-Cov and ZF2001 vaccines to SARS-CoV-2 501Y.V2. Lancet Microbe 2, e285 (2021).
123. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
124. Kibwmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African vaccine-elicited sera. J. Med. Virol. 93, 1826–1832 (2021).
125. Zalm, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutation escape seen with individual antibodies. Science 369, 1014–1018 (2021).
126. Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).
127. Gopalakrishna, Y. et al. The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J. Mol. Biol. 324, 47–62 (2002).
128. Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779–782 (2020).
129. Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsP12 polymerase bound to nsP7 and nsP8 co-factors. Nat. Commun. 10, 2342 (2019).
130. Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).
131. de Farias, S., Dos Santos Junior, A. P., Rêgo, T. G. & José, M. V. Origin and evolution of RNA-dependent RNA polymerase. Front. Genet. 8, 125 (2017).
132. Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).
133. Ledford, H. Hopes rise for coronavirus drug remdesivir. Nature https://doi.org/10.1038/d41586-020-01295-8 (2020).
134. Cardile, A. P., Warren, T. K., Martins, K. A., Reisler, R. B. & Bavarai, S. Will there be a cure for Ebola? Annu. Rev. Pharmacol. Toxicol. 57, 329–348 (2017).
135. Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - final report. N. Engl. J. Med. 383, 1813–1826 (2020).
155. Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695–1704 (2020).
156. Lawitz, E. et al. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet Gastroenterol. Hepatol. 18, 1115–1125 (2020).
157. Russmann, S., Grattagliano, I., Portincasa, P., Palmieri, V. O. & Palasciano, G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 13, 3351–3357 (2006).
158. Booth, C. M. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289, 2801–2809 (2003).
159. Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e434 (2006).
160. Naëns, L. et al. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol. Pharmacol. 84, 615–629 (2013).
161. Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105, 17–21 (2014).
162. Madelain, V. et al. Ebola virus dynamics in mice treated with favipiravir. Antivir. Res. 123, 70–77 (2015).
163. Bouazza, N. et al. Favipiravir for children with Ebola.
164. Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with favipiravir.
165. Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects.
166. Pan, H. et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity therapeutics report.
167. Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects.
168. Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors.
169. Pan, H. et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity assessment results.
170. Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects.
171. Bardsley-Elliot, A. & Noble, S. Oseltamivir.
172. Schoergenhofer, C., Jilma, B., Stimpfl, T. et al. Can recombinant soluble human ACE2 effectively neutralize SARS-CoV-2 as a possible COVID-19 therapy.
173. Devaux, C. A., Rolain, J. M. & Raoult, D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2.
174. Blanar, E. et al. The development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CL(pro) inhibitors.
175. Cai, Q. et al. Experimental treatment with favipiravir for COVID-19: an open-label, randomized, controlled, open-label, platform trial. Lancet 396, 1345–1352 (2020).
176. Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
177. Zhao, W. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
178. Heurich, A. et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
179. Heurich, A. et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
180. Heurich, A. et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
181. Khan, A. et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme II as a possible COVID-19 therapy.
182. Khan, A. et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme II as a possible COVID-19 therapy.
183. Cholankeril, G. et al. High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2: early experience from California.
184. Zhou, X. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.
185. Wang, Y. et al. A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells.
186. Zhou, X. et al. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a reprogramming complex.
187. Bouazza, N. et al. Favipiravir for children with Ebola.
188. Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with favipiravir.
Bunyavanich, S., Grant, C. & Vicencio, A. Racial/ethnic variation in nasal gene
Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a pro-
Yancy, C. W. COVID-19 and African Americans.

Signal Transduction and Targeted Therapy (2021) 6:317

Matsuyama, S. et al. Ef
Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome cor-

Menachery, V. D. et al. Pathogenic in

Borden, E. C. Interferons

El Baba, R. & Herbein, G. Management of epigenomic networks entailed in

Akira, S. Pathogen recognition by innate immunity and its signaling.

1. Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing

2. Sakai, K. et al. The host protease TMPRSS2 plays a major role in in vivo repli-

3. Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome cor-

4. Borden, E. C. Interferons

5. Menachery, V. D. et al. Pathogenic in

6. Borden, E. C. Interferons

7. Matsuyama, S. et al. Ef

8. Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing

9. Sakai, K. et al. The host protease TMPRSS2 plays a major role in in vivo repli-

10. Matsuyama, S. et al. Ef

11. Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome cor-

12. Sakai, K. et al. A mutant H3N2 influenza virus uses an alternative activation

13. Iwata-Yoshikawa, N. et al. TMPRSS2 contributes to virus spread and immuno-

14. Linn, D. E., Penney, K. L., Bronson, R. T., Mucci, L. A. & Li, Z. Deletion of interstitial

15. Yancy, C. W. COVID-19 and African Americans. JAMA 323, 1891–1892 (2020)

16. Linn, D. E., Penney, K. L., Bronson, R. T., Mucci, L. A. & Li, Z. Deletion of interstitial

17. Yamamoto, M. et al. Identification of Nafamostat as a potent inhibitor of Middle

18. Lin, B. et al. Prostate-localized and androgen-regulated expression of the

19. Bunyavanch, S., Grant, C. & Vicencio, A. Racial/ethnic variation in nasal gene

20. Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a pro-

21. Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a pro-

22. Al-Horani, R. A. & Desai, U. R. Recent advances on plasmin inhibitors for the

23. Yampa, W., Yu, H., Huang, S. & Zhu, P. Resveratrol protects against TNF-

24. Walsh, K. B. et al. Animal model of respiratory syncytial virus: CD8+ T cells cause

25. Sawalha, A. H., Zhao, M., Coit, P. & Lu, Q. Epigenetic regulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin. Immunol. 215, 108410 (2020).

26. Zhou et al. Therapeutic targets and interventional strategies in COVID-19:...
269. Xu, L., Botchway, B. D. A., Zhang, S., Zhou, J. & Liu, X. Inhibition of NF-κB signaling pathway by resveratrol improves spinal cord injury. *Front. Neurosci.* **12**, 690 (2018).

270. Howell, M. D., Kuo, F. I. & Smith, P. A. Targeting the Janus kinase family in autoimmune skin diseases. *Front. Immunol.* **10**, 2342 (2019).

271. Kalil, A. C. et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. *N. Engl. J. Med.* **384**, 2315–2324 (2021).

272. Kottyla, P. J., Engelmann, M., Giemsa-Stoklosa, J., Wnuk, B. & Islam, M. A. Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role? *Int. J. Mol. Sci.* **22**, 2449 (2021).

273. McInnes, I. B. et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. *Arthritis Res. Ther.* **21**, 183 (2019).

274. Cao, Y. et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. *J. Allergy Clin. Immunol.* **146**, 137–146.e133 (2020).

275. Migita, K. et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. *Clin. Exp. Immunol.* **175**, 208–214 (2014).

276. Dhillon, S. Tofacitinib: a review in rheumatoid arthritis. *Drugs** **77**, 1987–2001 (2017).

277. Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N. Engl. J. Med.* **376**, 1723–1736 (2017).

278. Pal Singh, S., Dammeyer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. *Mol. Cancer** **17**, 57 (2018).

279. Roschewski, M. et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci. Immunol.* **5**, eaab0110 (2020).

280. Treon, S. P. et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood** **135**, 1912–1915 (2020).

281. Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a membrane fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res.* **30**, 343–355 (2020).

282. Zhu, Y., Yu, D., Yan, H., Chong, H. & He, Y. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. *J. Virol.* **94**, e00635-20 (2020).

283. Xia, S. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell. Mol. Immunol.* **17**, 765–767 (2020).

284. Zhu, Y. et al. Design and characterization of cholesterylated peptide HIV-1/2 fusion inhibitors with extremely potent and long-lasting antiviral activity. *J. Virol.* **93**, e02312-18 (2019).

285. Chong, H. et al. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. *PLoS Pathog.* **16**, e1007552 (2019).

286. Chong, H. et al. Exceptional potency and structural basis of a T1249-derived lipopeptide HIV fusion inhibitor that enhances serpin inhibition of the cysteine protease cathepsin L. *Biochem. Biophys. Res. Commun.* **529**, 251–256 (2021).

287. Cao, Y. et al. Variable post-translational modifications of SARS-CoV-2 nucleosidic protein. *Glycobiology* **cwb044** (2021).

288. Cascarina, S. M. & Ross, E. D. A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation and regulation of biomolecular condensates. *FASEB J.* **34**, 9832–9842 (2020).

289. Poduri, R., Joshi, G. & Jagadeesh, G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. *Cell Signal.* **74**, 109721 (2020).

290. Cavassotti, C. N., Lamas, M. S. & Maggini, J. Functional and druggability analysis of the SARS-CoV-2 proteome. *Eur. J. Pharmacol.* **890**, 173705 (2021).

291. Rahman, M. S. et al. Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences. *J. Med. Virol.* **93**, 2177–2195 (2021).

292. Anand, K. et al. Structure of coronavirus main protease reveals combination of a chymotrypsin fold with an extra alpha-helical domain. *EMBO J.* **21**, 3213–3224 (2002).

293. Verkhratsky, A. H. et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. *J. Virol.* **78**, 13600–13612 (2004).

294. Klemm, T. et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. *EMBO J.* **39**, e106275 (2020).

295. Ospiuk, J. et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covariant inhibitors. *Nat. Commun.* **12**, 743 (2021).

296. Yuen, C. K. et al. SARS-CoV-2 nsP13, nsP14, nsP15 and orf6 function as potential interferon antagonists. *Emerg. Microbes Infect.* **9**, 1418–1428 (2020).

297. Liu, T., Luo, S., Libby, P. & Shi, G. P. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. *Signal Transduct. Target. Ther.* **6**, 134 (2021).

298. Gomes, C. P. et al. Cathepsin L in COVID-19: from pharmacological evidences to genetics. *Front. Cell. Infect. Microbiol.* **10**, 589505 (2020).

299. Sacco, M. D. et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. *Sci. Adv.* **6**, eaba0751 (2020).

300. Higgins, W. J., Fox, D. M., Kowalski, P. S., Nielsen, J. E. & Worrall, D. M. Heparin enhances serpin inhibition of the cysteine protease cathepsin L. *J. Biol. Chem.* **285**, 3722–3729 (2020).

301. Yousefi, B. et al. A global treatments for coronaviruses including COVID-19. *J. Cell. Physiol.* **235**, 9133–9142 (2020).
326. Breidenbach, J. et al. Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors. Angew. Chem. Int. Ed. Engl. 60, 10423–10429 (2021).

327. Li, Y. Y., Fang, J. & Ao, G. Z. Cathepsin B and L inhibitors: a patent review (2010-present). Expert Opin. Ther. Pat. 27, 643–656 (2017).

328. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534–537 (2011).

329. Liu, C., von Brunn, A. & Zhu, D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med. Drug Discov. 7, 100056 (2020).

330. Wang, K. et al. CD147-spike protein is a novel target for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 5, 283 (2020).

331. Sehirli, A. O., Sayiner, S. & Serakinci, N. Role of melatonin in the treatment of COVID-19, as an adjuvant through cluster differentiation 147 (CD147). Mol. Biol. Rep. 47, 8229–8233 (2020).

332. Zhai, Y. et al. CD147 promotes IKK/\(\kappa\)B pathway to resist TNF-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J. Mol. Med. 94, 71–82 (2016).

333. Ulrich, H. & Pillat, M. M. CD147 as a Target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev. Rep. 16, 434–440 (2020).

334. Reiter, R. J. et al. Mitochondria: central organelles for melatonin’s antioxidant and anti-aging actions. Molecules 23, 509 (2018).

335. Badeti, S., Tseng, H. C., Romanienko, P., Yehia, G. & Liu, D. Development of a novel human CD147 transgenic NSG mouse model to test SARS-CoV-2 infection and immune responses. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-396257/v1 (2021).

336. Travers, A. A. Priming the nucleosome: a role for HMGB proteins? EMBO Rep. 4, 131–136 (2003).

337. Mohanty, S. K. et al. HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants. Hepatology https://doi.org/10.1002/hep.31745 (2021).

338. Paudel, Y. N. et al. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: updates on receptor signalling. Eur. J. Pharmacol. 858, 172487 (2019).

339. Chen, L. et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell. Mol. Immunol. 17, 992–994 (2020).

340. Chen, R. et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon 6, e05672 (2020).

341. Adil, M. S., Verma, A., Rudraranj, M., Narayan, S. P. & Somanath, P. R. Akt-independent effects of triciribine on ACE2 expression in human lung epithelial cells: potential benefits in restricting SARS-CoV2 infection. J. Cell. Physiol. https://doi.org/10.1002/jcp.30343 (2021).

342. Wei, J. et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 76.e13–91.e13 (2021).

343. Bailly, C. & Vergoten, G. Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol. Ther. 214, 107618 (2020).

344. Gowda, P., Patrick, S., Joshi, S. D., Kumawat, R. K. & Sen, E. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Cytokine 142, 155496 (2021).

345. Cinatl, J. et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361, 2045–2046 (2003).